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Abstract
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is an effective
therapeutic option for many malignant diseases. However, the efficacy of allo-HSCT is limited
by the occurrence of destructive graft-versus-host disease (GVHD). Since allogeneic T cells are
the driving force in the development of GVHD, their activation, proliferation, and differentiation
are key factors to understanding GVHD pathogenesis. On the other hand, antigen-presenting
cells (APCs) are essential for allogeneic T-cell priming and the development of GVHD. The Tbox transcription factor T-bet is a master regulator for IFN-γ production and Th1 differentiation.
T-bet also regulates the functions of APCs including dendritic cells (DCs) and B cells. Therefore,
we investigated the role of T-bet in T cell responses, as well as on APC functions, in acute
GVHD (aGVHD) using murine models of allogenic bone marrow transplantation (allo-BMT).
In Chapter 2, we evaluated the roles of T-bet and IFN-γ in T-cell responses. T-bet-/- T
cells induced significantly less GVHD compared with either wild-type (WT) or IFN-γ-/counterparts in CD4-driven major histocompatibility complex (MHC)- or minor
histocompatibility antigen (miHA)–mismatched models. We defined several T-bet-dependent but
IFN-γ-independent molecules that may account for this distinct outcome. Further study indicates
that T-bet also controls the optimal activity of Th17 cells to induce GVHD. Moreover, the
compromised graft-versus-leukemia (GVL) effect of T-bet-/- T cells could be essentially reversed
by IL-17 neutralization. Thus, targeting T-bet or regulating its downstream effectors independent
of IFN-γ may be a promising strategy to control GVHD in the clinic.

viii

In Chapter 3, we evaluated the role of T-bet on APCs and found that T-bet-/- recipients
developed much milder GVHD than their WT counterparts in MHC-mismatched or CD4depedent miHA-mismatched models. As the functional readout of APCs, allogeneic donor T
cells, particular CD4 subpopulation, significantly reduced IFN-γ production, proliferation and
migration, and caused less damage in liver and gut in T-bet-/- recipients. We further observed that
T-bet on recipient hematopoietic APCs, particular DCs, was primarily responsible for donor Tcell response and pathogenicity in GVHD. In fact, Trail/DR5 interaction served as a major
signaling pathway responsible for donor T-cell apoptosis and impaired GVHD development in
T-bet-/- recipients. Furthermore, T-bet expression on the host is largely dispensable for the GVL
effect.
Taken together, we propose that T-bet is a potential therapeutic target for the control of
GVHD through regulating T cells as well as APCs. We believe further exploration and
understanding of the immunobiology of T-bet in controlling the activities of T cells and APCs in
GVHD will expand therapeutic options for the continuing success of allo-HSCT.
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Chapter 1: Background1

1.1 T-bet: a master regulator shaping immune responses
T-bet is a T-box family transcription factor encoded by Tbx21, which denotes “T-box
expressed in T cells” due to its original discovery in controlling the activity and function of T
helper type 1 (Th1) cells (1). While accumulating studies have shown that T-bet is expressed in
multiple immune cell lineages, including dendritic cells (DCs), natural killer (NK) cells, NKT
cells, and certain subsets of innate lymphoid cells (ILCs) in the innate immune system, as well as
CD4 and CD8 T cells, B cells, and γδ T cells in the adaptive immune system. Thus, T-bet serves
as a master regulator to shape immune responses and has been considered as a bridge to link
innate and adaptive immunity (2).

1.1.1 T-bet in innate immunity
The innate immune system provides the first line defense against infection. As one of the
major professional antigen presenting cells (APCs) in the innate immune system, DCs always
attract the attention of researchers. Shortly after T-bet was defined in Th1 cells (1), a different
study demonstrated that the expression of T-bet in human myeloid DCs could be induced rapidly
and directly by IFN-γ (3). The adjuvant activity of CpG DNA to control infection also requires
T-bet expression in murine DCs (4). Functional studies both in vitro and in vivo further indicated
Portions of this chapter have been previously published (Fu et al. Arch Immunol Ther Exp
(Warsz). 2014 Aug; 62(4):277-301.) and are utilized with permission of the publisher (p130).
1
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that T-bet is crucial for optimal IFN-γ production by DCs, and is required for antigen-specific
CD4 T-cell priming (5). Mechanistically, several signaling pathways have been identified
responsible for T-bet expression in DCs, including IFN-γ, IL-12, IL-18 and Toll-like receptor 9
(TLR9), among which the IFN-γ signaling seems to be the dominate pathway (4, 6, 7). Upon
interacting with T-cell receptor (TCR) on T cells, the DCs will produce IFN-γ and IL-12, which
then triggers T-bet-driven Th1 differentiation from naïve CD4 T cells (6). On the other hand,
overexpression of T-bet in DCs can enhance the surface expression of CXCR3 and IL-12Rβ2 on
CD4 T cells, and promote the granzyme B and IFN-γ production by CD8 T cells resulting in the
augmented tumor antigen specific CD8 T-cell responses (7). Therefore, the potential positive
feedback loop constituted by IFN-γ and T-bet in DCs play an important role to activate T cells,
connecting the innate and adaptive immune responses.
NK cells are able to rapidly respond to viral infection and tumors, because they kill the
target cells without recognizing MHC or producing antibodies. NKT cells are considered as a
heterogeneous group of T cells sharing the characteristics of T cells and NK cells, thus involving
both innate and adaptive immunity. The expression of T-bet is required for the development,
maturation, and function of both NK and NKT cells (8-10). T-bet-/- NK cells are immature and
sensitive towards apoptosis (8). Subsequent study revealed that the normal development and
terminal maturation of NK cells relies on the combination regulation of both T-bet and another
T-box transcription factor eomesodermin (Eomes) (9). The failure of IFN-γ production and
impaired survival of T-bet-/- NKT cells are possibly due to the low response to IL-15 receptor
signaling given the decreased expression of CD122 (IL-2 and IL-15 receptor β-subunit) (8).
However, despite of reduction in number, T-bet-/- NKT cells, are sufficient to induce the airway
hyperreactivity through the compensatory increase of IL-4 and IL-13 (11).

2

T-bet has also been shown to play a critical role to control the development and proper
function of ILCs, a family of cells regulating homeostasis and remodeling at mucosal sites,
particular group 1 and 3 with the dominate expression of transcription factor T-bet and RORγt,
respectively (12). T-bet+ ILC1s are responsive to IL-12 and IL-15, and can produce IFN-γ (13),
which was found to correlate with mucosal tissue inflammation in human Crohn’s disease (14).
The plasticity of ILC3s seems to be controlled by T-bet. T-bet expression in ILC3s leads to the
induction of IFN-γ and repression of IL-17 that is partially mediated through IL-7 receptor
signaling (15). The expression of T-bet was then identified in CCR6-, not CCR6+ ILC3 subsets,
which is positively related to the natural cytotoxicity receptor NKp46 expression and IFN-γ
production that is essential for protecting epithelial barrier against infection (16).

1.1.2 T-bet in adaptive immunity
The adaptive immune system consists of multiple highly specialized cells to eliminate
pathogens. The clonal expansion of T lymphocytes is initiated through TCR recognition of
specific pathogen-derived antigens presented by APCs. Unlike in the innate immune system,
effect of T-bet in the adaptive immune system has been extensively studied especially in CD4
and CD8 T cells (2).
Although naïve CD4 T cells do not express T-bet, it is actively induced through the
stimulation of TCR and IFN-γR signaling as the first wave, and IL-12R signaling as the second
wave (1, 17-19). T-bet self-induction did not occur when IFN-γ or IL-12 was present during Th1
differentiation, but this may happen through IFN-γ and IL-12-independent pathways (20). The
regulation of T-bet expression in Th1 cells also occurs at post-transcriptional or post-
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translational levels controlled by the microRNA-29 (21, 22) or the ubiquitin-dependent
degradation pathway which involves the Lys-313 in the T-box domain (23), respectively.
T-bet has a unique role in the differentiation of all three subsets (Th1, Th2, Th17) of
CD4+ Th cells by promoting the Th1 differentiation, while simultaneously inhibiting the
opposing Th2 and Th17 lineage commitment (24). This involves a complex epigenetic regulation
network (25). The bivalent histone H3 lysine 4 (H3K4me3) and H3K27me3 modifications reveal
the flexibility of master regulator expression in different lineages, particularly for the murine
Tbx21 locus (26). T-bet associates with RbBp5, a core component of H3K4 methyltransferase
complexes, and with JMJD3, a H3K27 demethylase (27). Epigenetic studies showed that T-bet is
able to mediate the removal of the repressive H3K27me3 mark at the Ifng and Cxcr3 promoters
and establish the permissive H3K4-methylation state in mice (27). The concomitant repression
or interference of other lineage-specific transcription factors, on the other hand, helps the
reinforcement of Th1 differentiation. For example, T-bet directly binds to Gata3 locus (28), or
indirectly binds to Il4 silencer site by forming a T-bet-RUNX3 complex (29), effectively
preventing Th2 differentiation. Similarly, T-bet binds to RORγt activator RUNX1 that prevents
Rorc (which encodes RORγt) and Il17 expression and impairs Th17 differentiation (30).
While T-bet predominately controls the production of IFN-γ by CD4 T cells (31), it has
cooperative and partially redundant function with Eomes in regulating homeostasis and cytolytic
activity of CD8 T cells (32-34). T-bet expression in CD8 T cells also relies on TCR and IL-12R
signaling, which accounts for the early activation of antigen-specific CD8 T cells. Then Eomes is
induced in a RUNX3-dependent manner, and substitutes T-bet to further produce IFN-γ and
granzyme B (35, 36). Once the pathogen clearance is achieved, a reservoir of memory CD8 T
cells is generated. T-bet expression is associated with effector memory T cells that are equipped
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with a more differentiated phenotype (37), while Eomes is more important for the maintenance
of central memory cells (38).
B cells can produce different antibodies in response to antigen stimulation, through a
process that includes affinity maturation and class-switch recombination. Studies show that T-bet
can regulate IgG class switching in B cells and thus control their autoantibody production (39).
IFN- γ, TLR9 and CD40 signaling induces T-bet expression in B cells, and leads to subsequent
induction of IgG2a, IgG2b and IgG3, but repression of IgG1and IgE (39-41). T-bet also regulates
the persistence and survival of IgG2a+CD38hi memory B cells through transcriptional regulation
of mature B cell receptor (42). Moreover, the migration of IgG2a+ memory B cells to
inflammatory sites is driven by T-bet through positively controlling chemokine receptor CXCR3
(43) .
T-bet is inducibly expressed in γδ T cells, a subset of the non-conventional T cells,
through TCR signaling (44). The cytokine production of γδ T cells, particularly IFN-γ, is
regulated by both T-bet and Eomes (45).

1.1.3 T-bet in disease
Given T-bet regulates various cell types in both innate and adaptive immune systems, it is
not surprising that T-bet plays a critical role in many diseases, which have been summarized in
Table 1.1. The effect of T-bet could be either beneficial or detrimental, depending on the types
of cells that are controlled by T-bet, and how they contribute to the pathogenesis of different
diseases. Graft-versus-host disease (GVHD), which occurrs after the allogeneic hematopoietic
stem cell transplantation (allo-HSCT), is our absolute focus in this dissertation.
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Table 1.1 Role of T-bet in regulating different diseases.
Disease

Role of
T-bet

GVHD

detrimental

Experimental
autoimmune
encephalomy
elitis (EAE)

detrimental

Cell
Type
Affected
CD4 T,
CD8 T;
APCs

Th1 and
Th17

dispensable Th17

Crohn's
disease

detrimental

Th1

ILC1s

Type 1
diabetes

detrimental

CD4 T
DCs

Evidence

Refs

- Control T-cell differentiation and function
through IFN-γ-independent manners;
- Regulate hematopoietic APC function to
promote allogeneic T-cell proliferation,
migration, and survival.

(46)
(47)

- T-bet-dependent pathway, such as IL-23R
signaling, but not pathway-specific end
products, such as IFN-γ and IL-17, contributes
to CD4 T-cell encephalitogenicity.
- T-bet-/- Th17 cells maintain/enhance GM-CSF
and IL-17 production, and are able to induce
EAE.

(49)
(50)
(51)

- Increased T-bet expression and IFNγ production in CD4+ T cells correlates with
disease development.
- T-bet+ ILC1s are responsive to IL-12 and IL15, and can produce IFN-γ contributing to
disease development.

(54)
(55)

- IFN-γ production controlled by T-bet in T
cells is a contributing factor.
- T-bet expression in DCs and CD4 T cells is
required for the initiation and later stage
pathogenesis, respectively.

(56)

(48)

(52)
(53)

(14)

(57)

Inflammatory detrimental
arthritis

DCs

- T-bet-/- DCs have compromised ability to
secrete proinflammatory mediators and to
prime naive T cells.

(58)

Asthma

Th2

- T-bet regulates the Th1/Th2 balance by
inhibiting Th2 differentiation and IL-4 and IL13 production to alleviate asthma.
- T-bet negatively regulates IgE production.

(59)
(60)

- T-bet regulates the Th1/Th17 balance by
inhibiting Th17 differentiation and IL-17
production to suppress allograft rejection.
- T-bet-/- RORγt-/- CD4 T cells drive Th2mediated allograft rejection.

(61)

beneficial

B cells
Allograft
rejection

beneficial

Th17

Th2,
Th17

6

(41)

(62)

1.2 Allo-HSCT, GVHD, and GVL
Allo-HSCT, previously known as allogeneic bone marrow transplantation (BMT), is a
transplant between two genetically non-identical individuals (63), which serves as an important
therapeutic option to treat various malignant and non-malignant diseases, including, acute and
chronic leukemias, lymphomas, multiple myelomas, aplastic anemias, solid tumors, and severe
immunodeficiency disorders (64). There is estimated to be more than 20,000 allo-HSCTs
performed annually around the world. Some patients present with remission of primary diseases
after allo-HSCT, however, in many cases patients develop a common secondary complication
named GVHD, in which transplanted cells injury the host tissues. GVHD accounts for 15–30%
of deaths following allo-HSCT and is a major cause of morbidity in up to 50% of transplant
recipients (63). The effectiveness of allo-HSCT for many malignant diseases is due to T-cell
mediated graft-versus-tumor (GVT) or graft-versus leukemia (GVL) effects. However, alloHSCT benefits are frequently offset by the destructive GVHD which is also induced by donor T
cells (65).
GVHD has a complex etiology but ultimately is the result of donor T-cells recognizing
disparate histocompatibility antigens (HA) of the recipient and causing injuries to normal tissues
(66). Murine models of GVHD are generally grouped into MHC-mismatched, or minor HAmismatched situations. GVHD develops in response to a full (class I and II) MHC disparity is
dependent on CD4 T cells and with additive pathology caused by CD8 T cells. Different from
CD4-dependent GVHD, CD8-induced GVHD primarily depends on the cytolytic machinery.
Either CD8 T cells, CD4 T cells, or both, may play a role in minor HA induced GVHD
depending on the strain combination. A majority of clinical allo-BMT recipients are MHC
matched but minor HA disparate with the donor, however, there is no one single mouse model to
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fully represent clinical setting of allo-HSCT (67). There are two forms of clinical GVHD: acute
GVHD (aGVHD) is characterized by damage to skin, liver, lung, and gastrointestinal tract.
Patients with aGVHD have increased risk of morbidity and mortality following allo-HSCT.
Chronic GVHD (cGVHD) has more diverse manifestations and many autoimmune-like
characteristics. Moderate to severe cGVHD substantially diminishes long-term survival as well
as quality of life for patients (68). GVHD has been postulated to occur in several stages (66, 69).
The first stage involves the cytoreductive conditioning and/or immunosuppression, which allows
for donor cell engraftment. Release of proinflammatory cytokines affects host APCs and helps
fuel the alloreactive donor T-cell response through alloantigen recognition. This is followed by
the “induction phase” in which TCR ligation and costimulation combine to achieve full T-cell
activation and subsequent expansion. As the alloreactive T cells expand, they differentiate into
different subsets; this is driven by the existence of certain transcriptional factors and cytokines.
Activated T cells further home to various GVHD target organs, a process controlled by adhesion
molecules, integrins, and chemokines. The production of chemokines in inflamed and injured
tissue also results in the recruitment of other cell-types (neutrophils, NK cells,
monocytes/macrophages) to the GVHD target organs further contributing to tissue injury. The
“effector phase” is noted for the destruction of host tissue by immune effector molecules (e.g.
FasL, perforin, granzymes, IFN-γ, and TNF-α) and results in the continued production of
proinflammatory cytokines that continually fuel the entire GVHD process (Figure. 1.1).
The challenge of allo-HSCT for treatment of leukemia and other malignancies of the
hematopoietic system is the prevention of GVHD without losing the GVL effect. GVL also
depends on donor T cells that recognize alloantigens and tumor-associated antigens. Various
strategies have been used in different murine models to successfully separate GVHD from GVL
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such as: depletion of alloreactive T cells, inhibition of inflammatory cytokines, interfering with
T-cell cytolytic pathways, co-stimulatory pathways and trafficking, infusing certain subsets of T
cells, and using immunosuppressive cell populations, including Tregs and NKT cells (70-72).
Despite its paradigmatic and clinical relevance, the mechanisms involved in the GVL effect are
still not completely understood and many currently used strategies to prevent GVHD impair Tcell function with deleterious GVL effects. However, advances are being made gradually by
documenting the potential of GVHD prevention and even with GVL augmentation, such as the
strategy of adoptively transfer murine or human Trail+ T cells to induce the fratricide of
alloactivated donor T cells (73).

Figure 1.1 Three phases of GVHD pathophysiology. Acute GVHD has been postulated to occur
in three sequential phases. (1) The initiation phase starts from conditioning regimen (e.g.,
irradiation) that makes “space” to allow for donor cell engraftment, but also causes host tissue
damage. Release of proinflammatory cytokines leads to increased expression of MHC and
adhesion molecules that enhance alloantigen presentation by host APCs to donor CD4 and CD8
9

T cells. (2) The induction phase involves TCR ligation and costimulation to achieve full T-cell
activation and subsequent proliferation. As the alloreactive T cells expand, they differentiate into
different subsets. This process is driven by the cytokine milieu through lineage-specific
transcription factors. Activated T cells release additional inflammatory cytokines, express
chemokine receptors, and migrate to various GVHD target organs. Chemokine production in
inflamed tissues recruits other cell types (NK cells, neutrophils, monocytes) to the target organ
sites, further contributing to GVHD pathology. (3) The effector phase is noted for the destruction
of host tissue by immune effector molecules, such as perforin, granzymes, IFN-γ, and TNF-α,
culminating in clinically evident GVHD.

1.3 Helper T-cell differentiation: general pathways and characteristics
T-cell activation, proliferation, and differentiation are considered determining factors for
GVHD development. Naïve CD4+ T cells can commit to particular lineages on the basis of
different modes of stimulation, antigen concentration, costimulation, and cytokine milieu. It is
well established that following activation, CD4 T cells will differentiate into either Th1
(secreting IL-2 and IFN-γ), Th2 (secreting IL-4, IL-5, and IL-13), Th17 (secreting IL-17, IL-21,
and IL-22), or Tregs (secreting IL-10 and TGF-β) (74). Several newly reported subsets of Th
cells, such as Th9, Th22, and T follicular helper cells (Tfh), also enriched our understanding
about T-cell differentiation. (75-77). Acute GVHD has been considered a Th1-type disease based
on the predominance of cytotoxic T lymphocyte (CTL)-mediated pathology and the increased
production of Th1-type cytokines, including IFN-γ (78, 79). However, Th17 cells have also been
implicated in the induction of experimental murine aGVHD (80, 81). In this section, we
summarize the general paradigms and characteristics among Th cells, including Th1, Th2, Th17,
and Tregs (Figure1.2).
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Figure 1.2 Pathways of helper T-cell differentiation: cytokines, transcription factors and
epigenetic modifications. Upon encountering cognate antigens presented by APCs, naïve CD4
T cells differentiate into different T helper subsets, including the classic Th1, Th2, Th17, Tregs,
or more recently defined Th9, Th22, or Tfh effector cells. Cytokines secreted in the
microenvironment during differentiation play a major role in dictating the phenotype of activated
CD4 T cells. T-cell lineages are further defined depending on the expression of transcription
factors, chemokine receptors, and effector cytokines, which are influenced by epigenetic
modifications. In the standard model, CD4 T cells can differentiate into Th1, Th2, Th17, or Treg
cells when activated in the presence of IL-12/IFN-γ, IL-4, IL-6/TGFβ, or TGFβ, respectively. Tbet, GATA3, RORγt, and Foxp3 have been well characterized and considered as the master
lineage determinants of Th1, Th2, Th17 and Treg cells, accordingly. T-bet leads to gene
silencing of Th2 and Th17 effector cytokines: IL-4 and IL-17 thus opening chromatin at Th1
cytokine or chemokine receptor gene loci, such as IFN-γ and CXCR3 activating transcription.
Likewise, GATA3 causes gene silencing of Th1 and Th17 effector cytokines: IFN-γ and IL-17
thus activating Th2 effector cytokines IL-4 and IL-13. CD4 T cells may also differentiate into
Th9, Th22, or Tfh subsets when activated in the presence of IL-4/TGFβ, IL-6/TNF-α, and IL-21,
respectively. They express lineage specific transcription factors, chemokine receptors, and
produce effector cytokines. Based on the respective cytokine profiles, responses to chemokines,
and interactions with other cells; these fully functional Th cells exert specific functions and
contribute to immune response. Different symbols represent the pathogenicity of different Th
subsets in GVHD. “+”: pathogenic effect; “-”: protective effect; “?”: non-conclusive effect.

1.3.1 The Th1/Th2 cell paradigm
Th1 and Th2 cells have two distinct cytokine secretion patterns that have been defined for
both murine and human Th cells (82). Mosmann and Coffman initiated Th1/Th2 paradigm in
1986, when their seminal work was published, which showed that murine CD4+ T-cell clones
could be characterized not only on the basis of their antigen specificity but also by their
functional skill sets, defined initially by differential cytokine secretion profiles (83). This
paradigm was further strengthened by equivalent findings from other groups, proving Th1 cells
distinctively produce IFN-γ, lymphotoxin, IL-2 and TNF-α. In contrast, Th2 cells produce their
signature cytokines: IL-4, IL-5, and IL-13. However, Th2 cells do produce lower levels of TNFα, GM-CSF, and IL-2 than Th1 cells (84, 85). Beyond the studies on lineage-specific cytokines,
critically important work from the groups of Zheng and Flavell (86) and Szabo et al. (1) further
identified lineage-specific transcription factors for Th1 and Th2 cells in mice. T-bet (Tbx21) was
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found to be the critical transcription factor for the generation of Th1 cells, whereas GATA3
served that role for Th2 cells. Evidence provided by different studies strongly suggests that the
cytokines play a major role in inducing the transcription factors that determine T-cell
differentiation (18, 87). Th1 cells are triggered by IL-12 and IFN-γ, and Th2 cells are triggered
by IL-4. With growing experience it has become clear that for Th1 and Th2 cells specialization
in patterns of cytokine production, transcription factors and other phenotypic characteristics do
occur in mice and in humans. The Th1/Th2 paradigm has been accepted for more than 20 years
(85). The differential development of these subsets allows for protective immunity against
specific pathogens. Th1 cells are important in mediating cellular immune responses and play a
critical role in the clearance of intracellular pathogens, whereas Th2 cells are mainly involved in
humoral immunity such as allergic immune responses and anti-parasitic immunity (88).

1.3.2 Differentiation and characteristics of Th17 cells
Th17 cells are highly proinflammatory cells that are part of the adaptive immune
response mounted against extracellular pathogens and also have been implicated in the induction
of several autoimmune diseases in mice (89). In the past nine years, an accumulation of
information on this popular T-cell subset (Th17) has been witnessed in both humans and mice:
The cytokines for its differentiation and expansion have been identified and the key transcription
factors that are involved in its generation have been elucidated (90). Murine IL-23 has long been
recognized to be an inducer of IL-17 (91). However, naïve murine T cells do not express the IL23R and do not differentiate into Th17 cells in the presence of IL-23 in vitro (92). Therefore, IL23 cannot be the sole inducer of Th17 differentiation although it appears to have a role in the
maintenance of effector function once these cells are induced (93). Other cytokines such as IL-6
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and IL-21 are implicated in the regulation and induction of IL-17 production by using gene
deficient mice (94, 95). In vitro, IL-6 is a potent inducer of Th17 cells but only when combined
with other cytokines including TGF-β (96). Thus, it appears the conjunction of TGF-β with IL-6
is the initial drivers of Th17 specification, and they can also activate the transcription factor
STAT-3, which is required for murine Th17 differentiation (97). However, full expression of the
Th17 phenotype depends on RORγt, which induces the expression of IL-17 and IL-17F,
contributes to the generation of IL-23R, and mediates IL-22 production in mice (98). In the
absence of IL-6, IL-21 in combination with TGF-β can function as an alternative signal for the
induction of Th17 cells (95). In disease models such as EAE that depend on Th17 induction, IL-6
seems to be more relevant than IL-21 (99). Other proinflammatory cytokines such as TNF-α and
IL-1β have also been shown to facilitate Th17 differentiation (100, 101).
Th17 cells are characterized by the production of several distinct cytokines that are not
typically secreted by Th1 and Th2 cells. In addition to the signature cytokine IL-17, Th17 cells
also preferentially secrete IL-17F, IL-21, IL-22, and, in humans, IL-26 (102). These cytokines
play important and non-redundant roles in enhancing the host defense against extracellular
pathogens. The receptors for IL-17 and IL-22 are broadly expressed on various epithelial tissues.
Thus, Th17 cells play critical roles in tissue immunity by mediating the crosstalk between
immune system and parenchymal tissues.

1.3.3 Interaction of Th17 cells with Th1, Th2, and Tregs
A balanced interaction among various T-cell subsets is very important in maintaining
immune homeostasis. Th1 and Th17 cells have a proinflammatory role and have been implicated
in many inflammatory conditions in humans and mice (103), while an anti-inflammatory role is
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attributed to Th2 and Treg cells. Th1 and Th2 cells inhibit the development of each other through
the actions of their lineage-specific cytokines IFN-γ and IL-4, respectively (104, 105). This
principle fits for Th17 cells as well, since the differentiation of Th17 cells can be inhibited by
IFN-γ or IL-4. However, once fully differentiated, Th17 cells are resistant to the suppressive
effects of IFN-γ and IL-4 in vitro (106, 107). Coexistence of Th17 and Th1 cells in inflammatory
lesions suggest their possible redundant function in pathology of murine experimental
autoimmune uveitis (108).
Another important aspect of Th17 cell differentiation is their relationship with Tregs.
Tregs can follow a developmental path similar to other T cells and emerge from the thymus
(referred tTreg or frequently as nTreg, for natural) or differentiate extrathymically from naïve
CD4+ T cells; Tregs in the latter subset are known as peripherally induced Treg cells (referred
pTreg, or frequently as iTreg, for induced) (109, 110). Tregs are critical for the maintenance of
immunological homeostasis and self-tolerance in humans and mice (111). These cells have been
classically defined as being CD4+ CD25+ and expressing the transcription factor Foxp3 (112).
Development of Th17 or Treg cells from induced murine naïve T cells has been suggested under
a mutually exclusive manner (113). IL-6 plays an important role in regulating the balance
between Th17 cells and Tregs in humans and mice. IL-6 induces the development of Th17 cells
from naïve T cells together with TGF-β; in contrast, IL-6 inhibits TGF-β-induced Treg
differentiation (114). Thus, IL-6 acts as a potent proinflammatory cytokine through promotion of
Th17 differentiation and inhibition of Treg differentiation indicating that this cytokine alters the
balance between effector and regulatory T cells. Moreover, Foxp3 itself is able to associate with
ROR-γt and inhibit ROR-γt transcriptional activation in mice (115).
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1.4 Helper T-cell subsets in GVHD: experimental and translational evaluations
GVHD is a major complication of allo-HSCT. Most of the knowledge about the
pathophysiology of GVHD has been derived from studies in mouse models. The differentiation
of Th cells requires coordinated cytokine signaling that induces the activation of specific
transcription factors and the production of linage specific cytokines to promote lineage-specific
CD4+ T-cell differentiation. Here we summarize the experimental and translational evaluations
of Th-cell subsets in GVHD, including the roles of important transcription factors and effector
cytokines, and their reciprocal differentiation features.

1.4.1 Transcription factors involved in T-cell differentiation in GVHD
The molecular mechanism by which a Th precursor adopts a Th1, Th2, Th17, or Treg
phenotype involves a complex interplay between the induction of lineage specific transcription
factors, such as T-bet, GATA3, RoRγt, and Foxp3, and the stimulatory effects of the cytokine
milieu which are largely provided by host APCs (116).
1.4.1.1 Th1: T-bet, STAT1, STAT4, c-Rel. Several transcription factors in coordination
induce full Th1 differentiation, including T-bet, STAT1, STAT4, and c-Rel. As one of the master
regulators that shape immune responses, T-bet has a unique role in the differentiation of all three
subsets (Th1, Th2, Th17) of CD4+ Th cells by promoting the Th1 differentiation, while
simultaneously inhibiting the opposing Th2 and Th17 lineage commitment (24). T-bet also
controls the expression of a subset of genes encoding molecules that influence the migration and
homeostasis of Tregs during Th1 cell-mediated immune responses (24). T-bet is a transcriptional
activator of IFN-γ (1), and the key regulator for the Th1 differentiation program. T-bet
orchestrates Th1 migration by directly controlling expression of chemokine receptor CXCR3 and
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chemokines CCL3 and CCL4 (117, 118). T-bet can also function as a repressor of certain genes
such as Socs1, Socs3, and Tcf7, that promotes the development of Th1 fate. T-bet physically
associates and functionally recruits the transcriptional repressor Bcl-6, to the Socs1, Socs3, and
Tcf7 promoter regions and represses their transcription (119). The repression of Socs family
members Socs1 and Socs3 is necessary to create functional Th1 cells. The repression of Tcf7 will
inhibit Th2 fate by sequestering the Th2-specific transcription factor GATA3 away from the Il5
and Il13 promoters. Runt-related transcription factors also participate in the differentiation
process. Runx1 and Runx3 were found to promote Th1 cell differentiation in coordination with
T-bet (29, 120). T-bet and Runx3 bind to Il4 silencer and prevent Il4 expression (24). In Th17
cells, T-bet interacts with Runx1 and blocks Runx1-mediated transactivation of Rorc, then
suppresses the Th17 lineage development (24). Our group previously showed targeting T-bet and
RORγt can prevent GVHD without offsetting GVL activity in allo-BMT murine models (47).
Our recent study also found that T-bet is critical for CD4 T-cell-mediated GVHD by controlling
T-cell differentiation and function, also the involvement of T-bet-dependent but IFN-γindependent molecules can partially explain the compromised ability of T-bet deficient but IFN-γ
sufficient CD4 T cells in murine GVHD induction (46).
STAT1 is another main signal transducer for IFN-γ (121). In response to IFN-γ
stimulation, STAT1 is activated and then initiates Th1 development. T-bet is induced by IFN-γ
and STAT1 signal pathway upon T-cell activation. Once triggered, T-bet in turn activates IFN-γ
expression, leading to autocrine and paracrine positive feedback effects on IFN-γ/STAT1
signaling and further controls Th1 differentiation (17). STAT1 activation in GVHD target tissue
and secondary lymphoid organs is one of the earliest events in GVHD induction (122). Ma et al.
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(123) showed that absence of STAT1 in donor CD4+ T cells promotes the expansion of Tregs
and reduces GVHD in mice.
STAT4 is another important transcription factor involved in the Th1 cell differentiation
(124). By inducing IFN-γ production, STAT4 creates a positive feedback loop for further T-bet
and IL-12Rβ2 expression. At later stages of differentiation, IL-12/STAT4 pathway upregulates
expression of IL-18Rα. IL-12 along with IL-18 induces IFN-γ production, independent of TCR
activation, thus creating a pathway for enhancing Th1 response (125). Nikolic et al. (126)
evaluated the role of STAT4 or STAT6 in the induction of aGVHD using gene deficient mice as
donors, and found that STAT4–/– donor T cells mediated aGVHD with delayed kinetics
compared with wild-type (WT) or STAT6–/– T cells. On the other hand, STAT6 was
indispensable for liver and skin GHVD.
c-Rel controls CD4 T-cell differentiation during diverse immune responses by using both
T-cell autonomous and nonautonomous mechanisms (127). Hlx, another transcription factor and
Th1 cell-specific homeobox protein, has been shown to synergize with T-bet in promoting the
transcription of IFN-γ (128). One explanation is that c-Rel might indirectly regulate the
expression of IFN-γ by controlling the levels of Hlx. The defect in IFN-γ production by c-Reldeficient Th1 cells could also be due to a remodeling failure at IFN-γ locus (129). Alternatively,
c-Rel could be involved in a pathway parallel to T-bet or serve as a common effector molecule
downstream of T-bet and STAT4 pathways. Thus, the precise position of c-Rel in the hierarchy
of the Th1 transcriptional cascade leading to the production of IFN-γ has not been defined yet.
Our group recently found that (130) T cells deficient for c-Rel have a dramatically reduced
ability to cause aGVHD after allo-BMT by using major and minor histocompatibility
mismatched murine models. Our data showed that c-Rel–/– T cells had a reduced ability to
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expand in lymphoid organs and to infiltrate in GVHD target organs in allogeneic recipients. cRel–/– T cells were defective in the differentiation into Th1 cells after encountering alloantigens,
but were enhanced in the differentiation toward Foxp3+ Treg cells. Furthermore, c-Rel–/– T cells
had largely preserved activity to mediate GVL response. Thus, c-Rel plays an essential role in T
cells in the induction of aGVHD.
1.4.1.2 Th17: RORγt, STAT3, AhR, and IRF4. The development of Th17 cells is
mainly dependent on the transcription factors RORγt, STAT3, AhR, and IRF4 (98, 131). RORγt
together with RORα synergistically directs the differentiation program of Th17 lineage and their
absence completely aborted Th17 development (131). Fulton and colleges (132) have evaluated
the role of Th17 cells in murine aGVHD by infusing donor T cells lacking Rorc. Their data
suggests that Rorc deficient T cells have reduced ability to induce aGVHD. However, our study
demonstrated that (47) RORγt alone plays little role on donor T cells in the induction of aGVHD,
but RORγt significantly control the T-cell pathogenesis in aGVHD in the absence of T-bet. Thus,
targeting both T-bet and RORγt can effectively prevent GVHD without offsetting GVL activity
in murine models of allo-BMT (47).
As one of GVHD-specific signaling pathways, STAT3 plays an important role in the
differentiation process by activating downstream IL-6, IL-21, and IL-23 signaling. It can also
induce RORγt expression by binding to IL-17A and IL-17F promoters (133). Deficiency of
STAT3 causes enhanced expression of T-bet and Foxp3, which are involved in the development
of opposing Th1 and Treg lineages, respectively (134). Ma et al. (135) reported that, STAT3
activation in the spleen correlated with high levels of IL-6 and IL-10. The marked change in IL6/IL-10 ratio during the development of GVHD could suggest that STAT3 may act as a promoter
of inflammation during the early priming and induction phase of GVHD (high IL-6/IL-10 ratio)
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and may mediate anti-inflammatory signals at later time points (low IL-6/IL-10 ratio). A study
from Lu et al. (136) also provides evidence that STAT3 and ERK1/2 phosphorylations are
critical for T-cell alloactivation and GVHD. Furthermore, by using conditional STAT3 knockout
mice as donors, Radojcic et al. (137) demonstrated that STAT3 is critical for CD4-driven
cGVHD.
Aryl hydrocarbon receptor (AhR) is a ligand-activated transcription factor with important
physiological roles in biological responses, such as controlling cell proliferation and
inflammation. Studies suggest that AhR promotes Th17 differentiation through the inhibition of
STAT1 and STAT5. However, absence of AhR did not completely abort Th17 differentiation,
but was associated with inability to produce IL-22 (138, 139). Activation of AhR by its
prototypic ligand, 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), induces potent suppression of
aGVHD in mice. Suppression is associated with development of a regulatory population of donor
CD4+ CD25+ T cells, but is independent of CTLA4-IFN-γ-IDO pathway (140).
BATF/IRF4 complexes are also involved in the transcriptional network to control Th17
differentiation. Cooperatively bound BATF and IRF4 contribute to the initial chromatin
accessibility and play a central role in RORγt-mediated activation of Th17 molecular signatures
(141). IRF4–/– mice failed to enhance expression of RORγt and subsequently did not develop
EAE as a result of impaired Th17 response (142). However, the role of IRF4 in the pathogenesis
of GVHD needs to be further investigated.
1.4.1.3 Tregs: Foxp3. As an important subset of Th cells, roles of Tregs in GVHD have
been widely investigated by us and others (143-146). Accumulating studies clearly indicate that
regulatory CD4+ T cells play a vital role in attenuating GVHD and are critically important for the
maintenance of tolerance (147-149). Tregs appear to uniquely express the Foxp3 transcriptional
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repressor. Foxp3 expression negatively correlated with the severity of GVHD in patients (150).
Clinical studies on recipients receiving BMT suggest that antigen-specific CD4+CD25+Foxp3+ T
cells play a critical role in the regulatory control of GVH reactions mediated by both alloreactive
and autoreactive lymphocytes (151).

1.4.2 Effector cytokines of distinct T-cell subsets: contribution to GVHD
1.4.2.1 Th1: IFN-γ, TNF-α, and IL-2. Acute GVHD has been proposed to be induced
by Th1 cells based on the predominant increased production of Th1-type cytokines, including
IFN-γ, TNF-α, and IL-2, which are detected in serum or donor T cells during aGVHD in both
humans and mice (152, 153). Paradoxically, the principal Th1 cytokine IFN-γ appears to be
unnecessary for GVHD induction and it can even inhibit the development of GVHD in lethally
irradiated allo-HSCT recipients (154-157). One study (155) showed that CD4+ T cells from IFNγ–/– mice resulted in accelerated GVHD after lethal total body irradiation (TBI) using a single
MHC- II mismatch model. In sharp contrast, the use of these same IFN-γ–/– CD4+ donor cells in
combination with sublethal TBI significantly ameliorated GVHD-associated mortality.
Administration of anti-IFN-γ antibodies to sublethally irradiated recipients of WT donor cells
confirmed the role of IFN-γ neutralization in CD4+ T-cell-mediated GVHD. Thus, opposite roles
of IFN-γ on CD4-mediated GVHD were shown to depend on different irradiation conditions.
The absence of IFN-γ is protective against GVHD in models using sublethal TBI, whereas
deleterious GVHD occurs in lethal TBI conditioning. Further studies indicate that IFN-γ plays a
protective role in lung, but a detrimental role for gut tissues (158, 159). IFN-γ specifically
suppresses lung GVHD through IFN-γR signaling in lung parenchymal cells (160, 161).
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TNF-α has been implicated to be involved in the pathophysiology of GVHD at several
steps. It participates in the initiating stage and amplifies the disease progression once established.
A series of clinical experiments demonstrated the strong correlation between TNFR1 levels and
GVHD supporting the importance of TNF-α in this process (162). Cooke et al. (163) found that
donor resistance to lipopolysaccharide significantly reduces the severity of aGVHD after
allogeneic BMT and that attenuation of early intestinal toxicity mediated by TNF-α is
responsible for this effect. TNF-α has both direct and indirect effect on GVHD: TNF directly
induce apoptosis on target tissues, and TNF indirectly activates T-cell proliferation pathways.
TNF-α has been used as a therapeutic target in preclinical GVHD models with promising results.
Soluble TNF receptors or monoclonal antibodies can be used to inhibit TNF-α
pharmacologically. Korngold et al. (164) have found that a chimeric rat/mouse anti-TNF-α mAb
could reduce the development of GVHD but preserve the GVL responses in murine models, with
a more significant effect in CD4- rather than CD8-mediated disease. Inﬂiximab is a genetically
constructed IgG1 murine-human chimeric monoclonal antibody against TNF-α. Binding of
infliximab to the soluble subunit of TNF-α blocks the interaction of TNF-α with its receptors and
causes cell lysis. Inﬂiximab was proven to be well tolerated and active for the treatment of
steroid-resistant aGVHD in patients (165). Further investigations are ongoing to define the
optimal dose and duration of TNF-α inhibition for GVHD prevention and treatment.
IL-2 was initially described as a T-cell growth factor. Given this knowledge, IL-2
treatment was initially used as a strategy to augment immune responses in cancer. Despite high
doses of IL-2 this treatment only induced modest antitumor responses; it also caused substantial
toxicities in patients with metastatic melanoma (166). Because IL-2 is a stimulant in the immune
environment, it initially has been expected to exacerbate GVHD rather than relieve it. But earlier
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studies found that IL-2 inhibits GVHD-promoting activity of CD4+ cells while preserving CD4and CD8-mediated GVL effects in mice (167). Two recent clinical studies (168, 169) using much
lower doses of IL-2 in different immune-mediated diseases suggesting that IL-2 may have a
dominant role in immunosuppression rather than in immune stimulation. It may also explain the
equivocal effects of IL-2 treatment seen in earlier clinical trials. Low dose of IL-2 administration
in patients after allo-HSCT suppressed the occurrence of cGVHD (168) and improved vasculitis
arising from chronic HCV infection (169). Increased numbers of Tregs were observed after IL-2
treatment in both studies. Given that Tregs have a high affinity for IL-2, meaning they bind
especially well to IL-2 at low concentrations, researchers theorized that low doses of IL-2 could
activate Tregs to a far greater extent than conventional effector T cells, thereby reducing the
immune response causing cGVHD (168). Another preclinical study showed the synergistic
effects of rapamycin and IL-2, displayed by increased expansion of donor-derived Tregs and
reduced lethal aGVHD in mice (170). IL-2 sets an example to represent the complex dynamic
state of the immune system involving both suppression and activation.
1.4.2.2 Th17: IL-17, TGF-β, IL-21, IL-23, and IL-6. Among investigators, a conclusive
role of IL-17 in GVHD development has not yet reached a consensus. Adoptive transfer of
highly purified ex vivo polarized murine Th17 cells results in a more aggressive disease that is
dependent on IL-17 (80, 81). However, IL-17−/− donor CD4+ T cells could attenuate, exacerbate,
or had no effect on GVHD depending on the model and knockout mouse strains used (159, 171,
172). Kappel et al. (171) found that IL-17−/− total T cells induced similar GVHD responses as
WT cells, although, when purified CD4+ IL-17−/− T cells were given, there was improved
outcomes regarding the prolonged median survival. They conclude that IL-17 contributes to the
early development of CD4+ T-cell-mediated GVHD by promoting production of
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proinflammatory cytokines; however, it is dispensable for GVHD and GVT activity by
unfractionated T cells. Yi et al. (172) obtained substantially different results using a similar
murine BMT model. IL-17−/− T cells were found to exacerbate GVHD and to accelerate recipient
mortality compared with WT T cells. Administration of exogenous IL-17 or neutralizing IFN-γ
could prevent the deleterious outcomes seen with IL-17−/− cells. This leads the investigators to
conclude that GVHD is exacerbated due to the augmentation of Th1 differentiation.
TGF-β plays critical roles in two antagonistically related Th cell subsets, Th17 and iTreg
cells. The conjunction of TGF-β with IL-6 is the initial driver of Th17 specification. Hill’s group
demonstrated that (173) neutralization of TGF-β after allo-BMT significantly increased aGVHD
severity in mice and the concurrent prevention of IL-10 production further exaggerated this
effect. Early after allo-BMT, donor T cells were the predominant source of TGF-β and were able
to alleviate aGVHD in a TGF-β-dependent manner. Although the neutralization of TGF-β
augmented the proliferation and expansion of donor T cells after allo-BMT, it paradoxically
impaired cellular cytotoxicity to host antigens and associated GVL effects. Different from the
protective effects in aGVHD, TGF-β contributed to the severity of cGVHD after allo-BMT.
IL-21 is produced by CD4+ T cells, especially Th17 cells (174) and NKT cells (175)
which signals through the IL-2Rγc and IL-21R complex. Recent reports show that inhibiting IL21 decreases disease severity in murine models of GVHD (176, 177). Genetically disrupting IL21 signaling or by using neutralizing mAbs could reduce transplant-related weight loss, tissue
pathology, and mortality. Disease amelioration correlated with decreased numbers of CD4+ T
cells secreting IFN-γ and a concomitant increase in the proportion of CD4+ T cells expressing
Foxp3, which is due to the conversion of CD4+ CD25− T cells into iTregs rather than preferential
expansion of nTregs themselves (176). Critical differences exist in how IL-21 functions in mouse
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and humans. IL-21 can act as the second signal required for Th17 polarization in humans (178),
whereas only IL-6 but not IL-21, has this function in mice (113). Blazar’s group established a
human xenogeneic GVHD model (179), and found that treatment of neutralizing mAb of human
IL-21 lead to significantly reduced GVHD-associated weight loss, mortality, increased Tregs,
and a decrease in T cells secreting IFN-γ or granzyme B in recipient mice. Based on these
findings, anti-IL-21 mAb could be considered for GVHD prevention in clinic.
By using genetic and antibody-based strategies, Das et al. (180) examined the effect of
blocking of IL-23 signaling on GVH and GVL activity after allo-BMT in mice. They
demonstrated that IL-23 blockade selectively protects the colon, specifically by attenuating gut
injury while still preserving the GVL effect. Interestingly, the colon did not serve as a sanctuary
site for subsequent systemic relapse in GVHD-protected mice since a potent GVL response
could be mounted in this organ under conditions where tumor cells migrated to this site. Thus,
blockade of IL-23 signaling is an effective strategy for separating GVH and GVL responses. IL23 could be a potential therapeutic target for the regulation of alloresponses in humans.
As a pivotal inflammatory cytokine in immune system, IL-6 plays important roles in
altering the balance between the effector and regulatory arms. It also drives a proinflammatory
phenotype that defines GVHD characteristics. Studies show that inhibition of the IL-6 signaling
pathway, by antibody-mediated blockade of the IL-6 receptor (IL-6R), markedly reduces
GVHD-caused pathologic damage in mice (181). This is accompanied by a significant increase
in the absolute number of Tregs and a significant reduction of Th1 and Th17 cells in GVHD
target organs. This demonstrates that blockade of IL-6 signaling decreases the ratio of
proinflammatory T cells to Tregs. However, another group (182) showed that a brief duration of
IL-6 inhibition in recipient mice did not increase the absolute numbers of mature donor Tregs.

25

This could be a consequence of the several key differences between the models, including the
dose of radiation, the infusion of unsorted splenocytes, and the duration of IL-6 blockade. Thus,
blockade of IL-6 with anti–IL-6R mAb therapy may be testable in clinical trials to prevent
GVHD in allo-BMT.

1.4.3 Reciprocal differentiation of Th1, Th2, and Th17 cells in GVHD
In addition to the well-established balance between regulatory and effector T cells, the
balance among Th1, Th2, and Th17 effector subsets also plays an important role in regulating Tcell immune response. In aGVHD, naïve donor CD4+ T cells recognize alloantigens on host
APCs and differentiate into Th subsets, but the role of Th subsets in GVHD pathogenesis was
incompletely characterized until six years ago when Yi et al. (159) published their study in which
they discussed the reciprocal differentiation and tissue-specific pathogenesis of Th1, Th2, and
Th17 cells in GVHD. They found that in an MHC-mismatched murine model (C57BL/6 →
BALB/c), donor CD4+ WT T cells predominantly differentiated into Th1 cells and preferentially
mediated tissue damage in the gut and liver. However, deficiency of IFN-γ in CD4+ T cells
enhanced Th2 and Th17 differentiation and exacerbated tissue damage in the lung and skin.
Absence of both IL-4 and IFN-γ augmented Th17 differentiation and caused preferential skin
damage. Deficiency of both IFN-γ and IL-17 led to further augmentation of Th2 differentiation
and idiopathic pneumonia. The tissue specific GVHD pathology elicited by Th1, Th2, and Th17
cells was partially associated with their tissue-specific migration, which is dependent upon
differential expression of chemokine receptors. Several studies have described the increased
expression of chemokines and chemokine receptors in GVHD (183, 184). The profile of
chemokine and chemokine receptor expression is diverse in different target organs of GVHD.
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The results obtained by Yi et al. (47) indicate that donor CD4+ T cells can reciprocally
differentiate into Th1, Th2, and Th17 cells, and each Th subset contributes to specific GVHD
target organ tissue damage. This study further enriches the content of the standard model for Th
differentiation, especially in aGVHD settings. Although Th2 cells may still be pathogenic to
certain tissues (e.g. lung), our recent work demonstrated that Th1 and Th17 subsets are the
primary driving force to induce aGVHD in mice, thus targeting these two subsets while
preserving or promoting Tregs may represent an effective strategy to control aGVHD (47).

1.5 Helper T-cell subsets in GVHD: clinical strategies

1.5.1 Current findings of the role of T-cell subsets in clinical GVHD
The pathogenesis of GVHD involves various Th-cell subsets. Each individual disease
manifestation appears to have a distinct T-cell milieu, which is determined by target structure
and inflammatory environment. Several aspects contribute to the understanding of T-cell subset
function in humans including cytokine quantifications in peripheral blood, lesion tissue biopsies,
or from single nucleotide polymorphisms (SNPs) of cytokine genes and their association with
GVHD (185-187). Much of the information about the role of T-cell subsets in clinical GVHD is
confusing and contradictory, which indicates that, the picture of GVHD etiology is likely more
complex in humans.
Despite the perceived skewing of GVHD toward a Th1 process, no study has found
increased serum levels of IL-12 in the patients after allo-HSCT compared with healthy donors
(188). Consistently, investigators have found increased expression for IL-6, TNF-α, and IL-1β,
which correlated with either disease severity (189, 190) or disease onset (186). Zhao et al. (191)
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found that, donor-derived Th17 cells in the allografts emerged as the independent risk factor
during the course of aGVHD in human, which suggests that IL-17-producing cells might be a
type of initiating cell in aGVHD. Recently, The Japan Donor Marrow Program analyzed
rs2275913, a SNP within the promoter region of the IL-17 gene and found that patients with this
SNP had increased IL-17 secretion increasing their risk of aGVHD (192). G-CSF treatment in
vivo reduced the occurrence of aGVHD through decreasing IL-17 production by T cells. In
accordance with the study reported by Zhao et al. (191), Dander et al. (193) found that the
peripheral blood of patients with ongoing GVHD showed an increased number of IL-17secreating T cells after transplantation, not surprisingly this increase was associated with the
clinical course of aGVHD. In contrast, Ratajczak et al. (194) demonstrated that Th17 cells in
human GVHD was not associated with any evidence of severe tissue damage at the onset of
disease, but the Th17/Treg ratio detected in lesion biopsies from gastrointestinal tract and skin is
positively correlated with the severity of aGVHD and serves as a sensitive and specific marker of
human GVHD. In addition, they detected significantly more IFN-γ producing T cells in biopsies
from affected areas. This data suggests that detection of individual T-cell subsets might not be
sufficient to reflect the complicated immune processes in human GVHD.

1.5.2 New approaches to target T-Cell differentiation for controlling GVHD in clinic
Tocilizumab, a humanized anti-IL-6R mAb, has been approved in several countries for
the treatment of rheumatoid arthritis and other inflammatory diseases. Administration of
tocilizumab has been reported to effectively reduce GVHD severity in the gastrointestinal tract
as determined by a marked reduction in the volume of diarrhea (195). A small-scale clinical
study in GVHD patients indicates that tocilizumab has activity in the treatment of steroid
28

refractory GVHD (196). Tocilizumab is currently under phase I clinical trial and the expected
effects are to decrease Th17 differentiation while increasing Treg induction in GVHD patients
(149). However, Betts et al. (197) did not observe an effect of tocilizumab on human monocytederived dendritic cells maturation and activation, alloreactive T-cell proliferation, Treg
expansion, or allogeneic Th1/Th17 responses in vitro, despite its on-target suppression of IL-6R
signaling (Figure 1.3). Therefore, the efficacy of tocilizumab on GVHD regulation warrants
further evaluation in clinic.

Figure 1.3 Therapeutic strategies to control GVHD by targeting of T-cell differentiation. (1)
Ustekinumab, anti-p40 mAb, binds to p40 subunit of IL-12 and IL-23 preventing their
interaction with IL-12Rβ1 on the T cell surface, thus, inhibiting IL-12 and IL-23 signaling. As
the consequence, Ustekinumab is expected to reduce the differentiation to Th1 and Th17 while
promoting the differentiation towards Th2 and Tregs. (2) Tocilizumab, anti-IL-6R mAb,
interferes IL-6 binding to IL-6R either membrane bound or soluble form, thus preventing the
dimerization of signal transducer gp130 and its interaction with IL-6/IL-6R complex. Treatment
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is expected to result in blocking Th17 differentiation and enhancing Treg generation. (3)
Rapamycin inhibits mTOR activation. In conventional T cells, diverse signals determine mTOR
activity, including ligated costimulatory molecule CD28, TCR, the cytokine IL-2, and its
receptor. Among the complex networks, signals are transduced through PI3K–AKT-mediated
pathway to activate mTOR. Upon activation, mTOR promotes Th1, Th2, and Th17
differentiation but reduces Treg differentiation by regulating their lineage specific transcription
factors. mTOR functions as part of the complexes mTORC1 and mTORC2. Rapamycin in
complex with the immunophilin FK506-binding protein 1A, 12 kDa (FKBP12) inhibits
mTORC1 and decreases the T-cell differentiation towards Th1, Th2, and Th17 while enhancing
Tregs. (4) Statins, HMG-CoA reductase inhibitor, blocks the conversion of HMG-CoA to
mevalonate and thereby prevents the formation of cholesterol and isoprenoids, which leads to the
inhibition of isoprenylation of small GTPases such as Ras, Rho, and Rac. This influences
multiple intracellular signaling pathways and cellular functions including proliferation and
differentiation. Statins causes preferential development of Th2 cells, as well as Tregs, and
inhibition of Th1-driven responses.

Ustekunimab (Stelara) is a humanized monoclonal antibody that directly binds to p40, a
subunit shared by IL-12 and IL-23. As a treatment utilized to regulate the immune-mediated
inflammatory disorders such as psoriasis, ustekunimab had not been previously used for GVHD
until Pidala et al. (198) observed its activity in a patient with advanced refractory aGVHD.
Ustekinumab was successful in inducing clinical remission of aGVHD in that patient and the
correlative data on peripheral blood serum cytokine production indicated the skewing of CD4+
T-cell repertoire from Th1 to Th2 and Tregs. Given that IL-12 and IL-23 are key drivers of the
differentiation of Th1 and Th17 cells responsible for GVHD (199, 200), use of ustekunimab to
target against both Th1 and Th17 may provide a powerful novel approach for GVHD prevention
(Figure 1.3). A comparative trial, lead by Dr. Pidala, is currently ongoing to assess the biologic
and clinical activity of ustekinumab in GVHD patients when given in concert with the
established regimen of sirolimus/tacrolimus.
Rapamycin (Sirolimus), a macrolide antibiotic produced by Streptomyces hygroscopicus,
is the prototypical inhibitor of the molecular target of rapamycin (mTOR). It has been used as a
prophylaxis and treatment in a number of immune disorders including GVHD (201, 202). Pidala
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et al. (203) provided preliminary evidence for the efficacy of sirolimus as a sole primary therapy
in the treatment of aGVHD. In a series of ten patients at high risk for corticosteroid toxicity or
leukemia relapse who developed grade II–III aGVHD after allo-HSCT, it was reported that
primary therapy with sirolimus resulted in durable complete remission of aGVHD in 5 (50%)
without requirement for glucocorticoids. Projected overall survival at 18 months is 79% and
projected relapse-free survival at 15 months is 70%. Several studies recently have reported the
use of gene targeting to disrupt mTOR function in lymphocytes conﬁrming an essential role for
mTOR signaling in T-cell differentiation (204). Complete deficiency of mTOR signaling (both
mTORC1 and mTORC2) abrogated the differentiation of Th1, Th2, and Th17 lineages, and
instead T cells were diverted into a Foxp3+ regulatory phenotype. This was associated with
reduced levels of activation of STAT transcription factors and subsequent failure to induce
expression of the Th1, Th2, and Th17 master regulators T-bet, GATA3, and RORγt (205).
Different groups report distinct roles for mTORC1 and mTORC2 in T cells although with
discrepancies (205, 206). Rapamycin induces in vitro expansion of nTreg (207), which has also
been used recently to establish good manufacturing practice for expansion protocols for human
CD4+CD25+ T cells (208). Rapamycin and IL-2 enable the expansion of donor-derived nTreg
and conversion of CD25– T cells to iTreg, which potently inhibits GVHD development in vivo
(170). Thus, the application of rapamycin in combination with IL-2 to get higher yields of nTreg
and iTreg represents a promising strategy of pharmacologic Treg modification to treat or prevent
GVHD (Figure 1.3). The main oral alternative to sirolimus is everolimus with slightly improved
bioavailability and the use of everolimus in refractory cGVHD has been reported by Lutz et al.
during the 38th Annual Meeting of the European Group for Blood and Marrow Transplantation in
Switzerland (209). Sirolimus and everolimus are currently under phase II/III or phase I clinical
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trials, respectively, and the expected effects are to decrease Th1 cell differentiation and retain or
increase Treg cells in GVHD patients (149).
HMG-CoA reductase inhibitors (statins) are prescribed worldwide for the prevention and
treatment of dyslipidemia and atherosclerosis (210). Statins can bind to HMG-CoA reductase
and displace its natural substrate HMG-CoA, leading to inhibition of mevalonate and cholesterol
biosynthesis. Cholesterol metabolism has been indicated to play an important role in modulating
T-cell proliferation and differentiation through liver X receptor signaling (211, 212). Stains can
also indirectly inhibit several posttranslational modification proteins such as Ras, Rho, and Rac,
through reduced mevalonate production (210). Thus, statins can further effect multiple
intracellular signaling pathways and cellular functions including differentiation, motility,
secretion, and proliferation (213). Atorvastatin is the prototypic statin drug that has a proven
safety track record (214). Inhibiting Ras leads to preferential development of Th2 cells and
inhibition of proinflammatory Th1-driven responses (213). This change in intracellular signaling
may also effect the development of Treg cells, as exposure of human CD4+ T cells to
Atorvastatin in vitro increased expression of Foxp3. Furthermore, patients with hyperlipidemic
who took statins up to eight weeks had more circulating Foxp3+ Treg cells (215). In addition to
direct effects on T cells, statins inhibit IFN-γ-induced expression of MHC-II and block
upregulation of a variety of costimulatory molecules and cytokines in APCs (213). Hamadani et
al. (216) performed a retrospective review of 67 individuals who had received allo-HSCT
containing T cells. They found that the rate of grade II–IV aGVHD in patients receiving statins
was 10%, compared with 40% in non-treated group. Also the progression-free survival at three
years in acute myeloid leukemia patients with or without statin use were 54 and 28%,
respectively, which indicates the preserved GVL effect in patients using statins at the time of
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allografting. Extensive preclinical and retrospective clinical data suggest that statins can prevent
aGVHD without decreasing GVL effects. In order to prospectively validate these observations,
phase-II clinical trials evaluating the role of Atorvastatin in preventing aGVHD is currently
ongoing. The expected effects are to inhibit development of Th1 cells and enhance the induction
of Th2 and Treg cells in GVHD patients (149, 217).

1.6 Roles of CD8 T cells in GVHD development and mediating GVL effect
T-cell alloreactivity is the key factor for the pathology of GVHD, and involves both
helper CD4 and cytotoxic CD8 T-cell subsets. Unlike CD4 T cells that are activated by
exogenous antigens presented by MHC-II molecules on recipient APCs, CD8 T cells are
activated by endogenous antigens presented by MHC-I molecules. GVHD which developes
across a full MHC disparity commonly requires both CD4 and CD8 T cells, with the dominant
contribution of CD4 T cells and the additive pathology provided by CD8 T cells (218). GVHD
can also develop even with matched MHCs but mismatched miHAs, where either CD8, or CD4
T cells, or both are able to induce the disease, depending on the donor/recipient strain
combinations (218). In MHC-mismatched systems, the GVHD target organ damages can occur
without the direct interaction between cognate T cells and the MHC expressed on tissues,
particularly in CD4-, to a lesser extent in CD8-, mediated GVHD which occurs at least partially
as a result of cytokine production (219). However, in miHA-mismatched systems, CD8 but not
CD4 T cells require TCR binding to MHC on target tissues in order to cause GVHD (220). Only
host APCs are able to stimulate CD8 T cells to induce GVHD in CD8-dependent systems (221).
Activated CD8 T cells will release perforin, granzymes and upregulate FasL to cause GVHD
(222, 223).
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In the aspect of mediating GVL effect, both CD4 and CD8 T cells require direct leukemic
contact (220). Among various types of cells (NK cells, CD4 T cells and CD8 T cells) that are
involved in GVL responses, CD8 T cells are considered as the major contributor due to their
potent alloantigen specificity (224, 225) and cytolytic activity (226, 227). The helper CD4 T
cells release cytokines and interact with APCs through costimulatory molecules and then
stimulate those APCs. The activated APCs provide a “license to kill” to cytotoxic CD8 T cells,
which is also important for the GVL effect (71). After donor CD8 T cells recognize the antigen
expressed by the host malignant cells, either alloantigens or tumor-associated antigens, they will
further lyse the target cells through similar mechanisms involved in GVHD, including the
perforin-granzyme pathway alone, or in combination with FasL-Fas pathway (228). Exposure
and mobilization of lysosomal-associated membrane protrin-1 (LAMP-1/CD107a) during
perfoin/granzyme-mediated lysis is well correlated with cytotoxic activity of CD8 T cells (229,
230).

1.7 Effect of APCs in GVHD and GVL
APCs are essential to induce GVHD and mediate GVL reactions due to their ability to
integrate and prime T cells. Multiple cell types from either the hematopoietic or
nonhematopoietic compartments may participate in antigen presentation process with distinct
efficiencies (231, 232).

1.7.1 APCs populations
1.7.1.1 Hematopoietic APCs. DCs, B cells, and macrophages are the major
hematopoietic APCs that are also considered as the professional APCs with a specialized ability
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to process and present antigens onto MHC molecules. These professional APCs have distinct
circulatory patterns and occupy different locations. Conventional DCs can be divided into
migratory DCs and resident DCs. Migratory DCs include the skin epidermal Langerhans cells
and dermal DCs that uptake antigen from peripheral tissue and present it in the lymph nodes.
Resident DCs, such as splenic or thymic DCs, load and process antigen within lymphoid organs
(233, 234). Overall, DCs are the most effective APCs to prime T cells although depending on
their origin and activation status. The activated conventional myeloid DCs can produce IL-12
and promote Th1 differentiation, as well as cytotoxic CD8 T-cell responses (233). Naïve B cells
recirculate between peripheral blood and secondary lymphoid organs without presenting in the
skin or majority of the mucosal sites. They uptake antigens through B-cell receptor (BCR) and
present on MHC-II molecules that interact with CD4 T cells, and generate efficient antibody
responses (235). Macrophages are strategically stationed at various locations throughout the
body and perform their immune surveillance function. When danger signals such as tissue
damage occur, they are actively recruited to the inflammatory sites and prepare to stimulate
lymphocytes to combat pathogens (236).
1.7.1.2 Nonhematopoietic APCs. Nonhematopoietic APCs include diverse types of
cells, such as epithelial cells, endothelial cells and myofibroblasts, which can be induced to
express MHC-II and develop antigen-presenting abilities under specific conditions. IFN-γ is the
major effector cytokine to induce MHC-II expression both in vitro and in vivo, and likely enable
those nonhematopoietic APCs to modulate either effector or memory CD4 T cell responses
under inflammatory conditions (237). Nonhematopoietic APCs are distributed in different organs
including the liver, intestine, and lung that are frequently targeted by allogeneic T cells during
GVHD development (174, 237).
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1.7.2 Pathways of antigen presentation after allo-HSCT
There are two pathways of antigen presentation after allo-HSCT, direct presentation
mediated by host APCs and indirect presentation mediated by donor APCs (238). Host
alloantigens, either endogenous or exogenous, can be directly presented by host APCs to donor
CD8 or CD4 T cells. Alternatively, host allogeneic MHC antigens or miHAs may be
crosspresented by donor APCs to donor T cells. Direct presentation is likely to be predominant
during early stages of aGVHD, given that no GVHD was induced in mice lacking MHC-I on
host APCs despite the capacity of donor APCs to perform cross-presentation (221). However,
indirect presentation driven by donor APCs may contribute to further tissue injury thus
intensifying the aGVHD (239, 240). Moreover, CD4-dependent GVHD could be induced
through either host or donor APCs (241), whereas only host APCs will initiate CD8-dependent
GVHD (221).

1.7.3 Effect of APCs in GVHD
1.7.3.1 DCs in GVHD. After lethal conditioning, radiosensitive DCs and precursor cells
derived from the host are lost within the first few days after allo-BMT. However, that period of
time is long enough for host DCs to prime donor T-cell activation, and initiate their proliferation
and differentiation. Studies show that host CD11c+ DCs were activated and accumulated in the T
cell areas of the spleen within 6 hours of lethal irradiation. After 5 days, even though less than
1% of host DCs were detectable, the primed donor CD8 T cells had undergone seven divisions
which is sufficient to trigger GVHD in miHA-mismatched recipients (242). Adding back MHCII+/+ host-derived DCs, but not B cells, into MHC-II-/- mice could effectively break the resistance
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of GVHD development in CD4-dependent model. Similar results were seen in CD8-dependent
model although to a lesser extent (243). This demonstrates that host DCs rather than host B cells
are critical in priming donor CD4 and CD8 T cells to induce GVHD. Moreover, persistence of
host DCs is positively correlated with aGVHD (244, 245).
After the first few days post-transplant, the vacancy in host APC numbers is filled by
differentiated APCs contained within the donor graft or by other donor BM progenitordifferentiated cells (238). Although the kinetics of full functional reconstitution are not clear,
numerical recovery of DCs and macrophages has been shown to be more rapid than that of B
cells (246). In preclinical murine BMT models, conventional DCs have been proved to be the
critical donor APCs to induce GVHD, compared with macrophages or B cells (247). Clinical
studies have documented that low numbers of circulating CD11c+ DCs in peripheral blood at the
time of engraftment were associated with the increased risk for relapse, aGVHD and death aftter
allo-HSCT, which may be explained by the increased DC homing to lymphoid tissues or GVHD
target organs, and the lack of regulatory DCs (248).
However, recent studies suggested that absence of recipient DCs using induced or
constitutive depletion of CD11c+ conventional DCs exacerbates aGVHD when all other APC
subsets are intact (249, 250). These findings have refined our understanding of APCs in GVHD,
and warn against the strategies of simply targeting APCs especially DCs as a means to alleviate
GVHD (233, 251).

1.7.3.2 B cells in GVHD. The effect of B cells in aGVHD is still controversial. The
effectiveness of B-cell depletion to reduce aGVHD in both mice (252) and humans (253-255)
has demonstrated the pathogenic role of B cells, either donor-or host-derived. The timing of early
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B-cell depletion by administrating rituximab seems crucial for its beneficical effects in aGVHD
(256). In contrast, other studies have shown the protective effect of B cells. Host B cells, but not
DCs within the spleen, are able to secret IL-10 after total body irradiation (TBI), thereby
inhibiting the expansion of allogeneic T cells and the induction of aGVHD (257). Donor B cells
have also been shown to alleviate aGVHD through a Treg-dependent mechanism (247, 258).
1.7.3.3 Macrophages in GVHD. Similar to B cells, a consensus on the roles of
macrophages in GVHD has not been reached. A study evaluating human sequential biopsy
indicated that host macrophages contributed to GVHD through antigen presentation and cytokine
production, leading to the activation and proliferation of CD8 T cells, and cytokine expression of
memory CD4 T cells. The persistence of host macrophages is likely contributing to GVHD by
maintaining the activated T-cell responses (259). However, a later study suggested that host
macrophages which persist after conditioning can engulf donor alloreactive T cells and prevent
their proliferation. As a result, preemptive CSF-1 therapy can ameliorate GVHD by expanding
host suppressive or regulatory macrophages (260).
1.7.3.4 Nonhematopoietic APCs in GVHD. Recent studies provide compelling evidence
that hematopoietic APCs may not be essential for aGVHD induction, due to host
nonhematopoietic APCs being sufficient to induce lethal aGVHD in mice (249, 250, 261). It has
been known that nonhematopoietic cells could express MHC-II occasionally, such as within the
gut and thymus (262, 263). The potential nonhematopoietic APCs that initiate GVHD include
epithelial cells, endothelial cells and myofibroblasts, as suggested by different studies (249, 261).
However, many aspects are still unknown regarding the mechanism of nonhematopoietic APCs
to induce GVHD. For instance, where does the nonhematopoietic antigen presentation and
alloactivation occur? Within the target tissues or in the context of stromal cells within secondary
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lymphoid organs? Another possibility has been suggested by a recent study, where the donor
DCs could incorporate the recipient MHC into their own membranes and indirectly mediate the
nonhematopoietic antigen presentation (264).

1.7.4 Roles of APCs in mediating GVL effect
Both alloantigens and tumor-specific antigens (TSAs) can initiate GVL responses (70,
265). APCs are well known for inducing alloantigen-specific responses, demonstrating their
importance for mediating GVL (266). Host APCs are predominated for full GVL effects, while
donor APCs can also initiate GVL activity with low tumor bulk (239, 266). Given the host
tumors express both alloantigens and TSAs, even if they perform antigen-presenting features, it
is likely undergoing immune editing that results in ineffective T-cell response through multiple
suppressive mechanisms (267). Recently, a subset of host–derived CD8+ DCs is suggested to
play a critical role in enhancing TSA responses, and is required for optimal GVL effects (268).
In the settings of delayed lymphocyte infusion (DLI), GVL can occur without GVHD (269).
Here the GVL activity is dependent on MHC alloreactivity and little or no GVL activity against
miHAs or TSAs is detected (269).

1.7.5 Strategies to targeting APCs in allo-HSCT
The strategies to manipulate the functions and/or numbers of APCs to achieve therapeutic
benefit of allo-HSCT have been reported and are still under active investigation (233, 238, 270).
Below is a summary of major interventional strategies on APCs, particular DCs, during
experimental or clinical allo-HSCT (Table 1.2).
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Table 1.2 Interventional strategies on APCs in allo-HSCT.
Therapy
Target
Outcome
+
Alemtuzumab CD52 DCs and T - Alloreactive
(Campath-1H) cells
stimulatory
activity in vitro ↓
- Human aGVHD↓

Evidence
- Depletion of CD52+ myeloid
DCs from peripheral blood
but not epidermis or gut.
- Depletion of CD52+ T cells.

CMRF-44
IgM Ab

Langerhans cells
(LC) and
peripheral blood
DC express
CMRF-44 antigen
CD83+ activated
DCs

- Number of
migratory LC ↓
-Allostimulation
by LC in vitro ↓

- Induces LC-depletion by
complement-mediated
cytotoxicity in vitro

- Allogeneic T cell
proliferation ↓
- aGVHD ↓
- GVL preserved

IMMU-114
mAb

HLA-DR+ APCs
(B cells,
monocytes, DCs)

- APCs apoptosis↑
- Alloreactive Tcell proliferation ↓

SAHA or
ITF2357

Histone
deacetylase
(HDAC) in DCs

Bortezomib

Proteasome in
immature DCs

- Allostimulatory
responses of DC ↓
- Murine aGVHD
↓
- GVL preserved
- Allogeneic T-cell
proliferation ↓;
Th1 ↓
- Immature DCs
apoptosis ↑
- Murine or human
aGVHD ↓
- GVL preserved

Regulatory
DCs (rDCs)

DC/T-cell
interaction microenvironment

- Murine aGVHD
and cGVHD↓
- GVL preserved

Genetically
modified
Trail-DCs

DC/T-cell
interaction microenvironment

- Murine aGVHD
↓
- GVL preserved

- Induce lysis of activated
CD83+ DCs.
-Spare pre-existing donor T
cells, including those target
viruses and malignant cells.
- A humanized anti- HLA-DR
mAb, efficiently deplete all
APCs with little direct effect
on T cells.
- Reduce proinflammatory
cytokine production,
costimulatory molecule
expression by DCs.
- Increase expression of IDO.
- Inhibit phenotypic and
functional maturation and
induce more potent apoptosis
in immature DCs through
suppression of NF-κB
activity.
- Decrease allogeneic T-cell
proliferation and increase
their apoptosis.
- rDCs displayed high levels
of MHC molecules and
extremely low levels of
costimulatory molecules.
- Generation of donor
inducible Tregs and anergic,
Ag-specific CD4+ T cells.
- Induce alloreactive T-cell
and tumor-cell apoptosis
through Trail-DR5 pathway.

Anti-CD83
polyclonal Ab
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(275)
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Chapter 2: T-bet is Critical for the Development of Acute Graft-versus-Host Disease
through Controlling T cell Differentiation and Function2

2.1 Abstract
T-bet is a master regulator for IFN-γ production and Th1 differentiation. We evaluated
the roles of T-bet and IFN-γ in T cell responses in acute GVHD and found that T-bet-/- T cells
induced significantly less GVHD compared with wild-type or IFN-γ-/- counterparts in both MHCmismatched and MHC-matched but miHA–mismatched models driven by CD4 T cells. T-bet-/-,
but not IFN-γ-/-, CD4 T cells had a markedly reduced ability to cause tissue damage in liver and
gut. This distinct outcome is reflected by the differential gene expression on donor CD4 T cells
deficient for T-bet or IFN-γ. At mRNA and protein levels, we defined several T-bet-dependent
molecules that may account for the impaired ability of T-bet-/- T cells to migrate into target
organs and to produce Th1-related cytokines. Moreover, these molecules were independent of
either endogenous IFN-γ, such as CXCR3 and programmed death-1 (PD-1), or systematic IFN-γ,
such as NKG2D, I-Ab, and granzyme B (GZMB). Although both T-bet-/- and IFN-γ-/- CD4 T
cells are prone to differentiate into Th17 cells, polarized Th17 cells deficient for T-bet but not for
IFN-γ had a significantly reduced ability to cause GVHD. Finally, T-bet-/- T cells had a
compromised GVL effect, which could be essentially reversed by neutralization of IL-17 in the
recipients. We conclude that T-bet is required for Th1 differentiation and migration, as well as

This chapter have been previously published (Fu et al. J Immunol. 2015 Jan 1;194(1):388-97.)
and are utilized with permission of the publisher (p131).
2
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for optimal function of Th17 cells. Thus, targeting T-bet or regulating its downstream effectors
independent of IFN-γ may be a promising strategy to control GVHD in the clinic.

2.2 Introduction
GVHD is a major limitation for the efficacy of allo-HSCT in the treatment of
hematologic malignancies because it leads to significant morbidity and mortality (63). The
cytokine storm caused by conditioning and Th1-cell cytokines produced by allogeneic T cells are
the driving forces for the initiation and development of GVHD (78, 152, 153, 286).
Paradoxically, the principal Th1 cytokine, IFN- γ, plays a dispensable role for GVHD
development in some experimental murine BMT models (154-157, 287, 288), where exacerbated
GVHD was observed in hosts receiving IFN-γ-/- grafts (155, 157, 287, 288) or after IFN-γ
neutralization (287) following lethal irradiation. On the other hand, administration of
recombinant IFN-γ showed a protective effect for CD4 T-cell mediated GVHD (154) .

T-bet, the T-box transcription factor, has a unique role in the differentiation of all three
subsets (Th1, Th2, Th17) of CD4+ helper T cells by promoting Th1 differentiation, while
simultaneously inhibiting Th2 and Th17 lineage commitment (24). T-bet target genes have been
identified in primary human T cells, which show that T-bet is associated with genes of various
functions in Th1 cells, including those with roles in transcriptional regulation, chemotaxis, and
adhesion (117). T-bet is a transcriptional activator of IFN-γ (1) and orchestrates the cellmigratory program by directly controlling expression of the chemokine receptors CXCR3 and
CCR5, as well as the chemokines CCL3 and CCL4 (117, 118). T-bet also has cooperative and
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partially redundant functions with Eomes, another T-box transcription factor, to control CD8 T
cell cytotoxicity and IFN-γ production (32, 33).

Previously, we observed that T cells deficient for T-bet are impaired in the induction of
acute GVHD (47). However, the effect and mechanism of T-bet on T cells to induce GVHD and
mediate the GVL effect has not been thoroughly studied, particularly the reason for the
paradoxical outcomes of GVHD caused by T-bet-/- or IFN-γ-/- T cells. We therefore utilized T
cells from T-bet-/- or IFN-γ-/- mice as donors and tested whether T-bet could be a potential target
for preventing GVHD after allo-BMT. We then elucidated the underlying mechanisms by which
T-bet or IFN-γ differentially regulates allogeneic T-cell response after allo-BMT. We identified
several molecules that depend on T-bet, but not on endogenous IFN-γ produced by donor T cells
or systematic IFN-γ produced by any type of cell, which may be responsible for T-cell
pathogenicity in GVHD induction. Furthermore, we define the role of T-bet in Th17 function
related to GVHD and its impact on the GVL effect. Our study provides new biological insight on
T-bet, as well as the rationale to target T-bet or its downstream effectors, to control GVHD after
allo-BMT.

2.3 Materials and methods

2.3.1 Mice
C57BL/6 (B6; H-2b, CD45.2), B6.Ly5.1 (CD45.1) and BALB/c (H-2d) were purchased
from National Cancer Institute (NCI, Frederick, MD). T-bet-/-, IFN-γ-/- and IFN-γR-/- mice on B6
background and founders of C.B10-H2b/LilMcdJ (BALB.B; H-2b) mice were purchased from
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The Jackson Laboratory (Bar Harbor, ME). BALB.B mice were bred at H. Lee Moffitt Cancer
Center (Moffitt, Tampa, FL). All animals were housed in the American Association for
Laboratory Animal Care–accredited Animal Resource Center at Moffitt or Medical University of
South Carolina (MUSC, Charleston, SC). Experiments were carried out under protocols
approved by the Institutional Animal Care and Use Committee of University of South Florida
(Tampa, FL) or MUSC.

2.3.2 BMT models
T-cell purification from whole spleen and lymph nodes was done by negative depletion
using magnetic beads as previously described (47). MHC- and miHA-mismatched
(B6→BALB/c) or MHC-matched but miHA-mismatched (B6→BALB.B) BMT models were
used as previously established (289). Briefly, 8-10 week old recipient mice were conditioned
with total body irradiation (TBI) based on weight at 750 to 850 cGy (single dose) for BALB/c
and 900 to 950 cGy (split 3 hours apart) for BALB.B using a Shepherd Mark I Cesium Irradiator
(J. L. Shepherd and Associates, San Fernando, CA) at Moffitt, or at 650 to 750 cGy (single dose)
for BALB/c using an X-RAD 320 X-ray Irradiator (Precision X-ray Inc., North Branford, CT) at
MUSC. Within 24 hours post-conditioning, recipients were intravenously injected with T-cell
depleted (TCD) BM alone with or without T cells from different strains of donors. Recipient
mice were monitored for weight loss and other clinical signs of GVHD twice/week. Clinical
scores were tabulated as 5 parameters: weight loss, posture, activity, fur texture, and skin
integrity. Individual mice were scored 0 to 2 for each criteria and 0 to 10 overall (290). A GVL
model was established by intravenously injecting luc/neo plasmid-transduced A20 B-cell
lymphoma cells (A20-luc) on BALB/c background the day of BMT (2×103 A20 cells/mouse). In
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addition, recipients were treated with anti-IL-17 mAb (clone: 17F3; Bio X Cell, West Lebanon,
NH) or PBS control at doses and schedules specified. Tumor growth was measured with
bioluminescent imaging (BLI) using Xenogen-IVIS ® 200 Pre-clinical In vivo Imaging System
(Perkin-Elmer, Waltham, MA) and analyzed by Living Image Software (Perkin-Elmer) as
previously described (291). Tumor and GVHD mortality were distinguished by BLI signal
intensity and clinical manifestation of GVHD. Recipients at pre-moribund stage were
euthanized and counted for lethality. Representative samples of GVHD target organs were
excised from recipients 14 days post-BMT and subjected to pathology scoring as previously
described (47, 291).

2.3.3 Flow cytometry and serum cytokine detection
Mononuclear cells were isolated from recipient spleen or liver as previously described
(47, 291, 292) and stained for surface receptors and intracellular cytokines using standard flow
cytometric protocols. Stained cells were analyzed using Diva software, LSR II (BD Biosciences,
San Jose, CA), and FlowJo (TreeStar, Ashland, OR). Cytokine levels in recipient serum were
quantified using a cytometric bead assay (BD Biosciences, San Jose, CA) (293).

2.3.4 Microarray and real-time PCR
Lethally irradiated BALB/c mice were transplanted with WT Ly5.1+ B6 TCD-BM (5 ×
106/mouse) plus WT, T-bet-/- or IFN-γ-/- naïve CD4+ Ly5.1- T cells (1 × 106/mouse). Recipients
were euthanized on day 7. Donor-derived T cells (CD4+ H-2Kb+ Ly5.1- DAPI-) in recipient
splenocytes were isolated by cell sorting (BD FACSAria II Cell Sorter), and lysed in TRIzol
(Life technologies, Grand Island, NY) to extract total RNAs. Microarray analysis was performed
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using GeneChip Mouse Genome 430 2.0 arrays (Affymetrix, Santa Clara, CA). Array images
were analyzed and processed by robust multi-array average (RMA) procedure (294, 295). Heat
map was generated by using Cluster 3.0 and Java TreeView. In order to identify potential genes
significantly changed (either increased or decreased) in the T-bet-/- versus WT group, but not
shared by the IFN-γ-/- group, three sets of genes were selected: 1) signal fold change of T-bet-/vs. WT >2; 2) signal fold change of T-bet-/- vs. IFN-γ-/- >2; and 3) signal fold change of IFN-γ-/vs. WT >2. Fold change calculation was based on the mean value of individual values from three
independent experiments. The genes overlapped in set 1 and set 2 were further selected, and
genes from set 3 were excluded from those selected genes. The signal value below 500 is
considered as background noise. Thus, the primary pool of T-bet-dependent but endogenous
IFN-γ-independent genes was established. Additional criteria were added when heat map
analysis was performed. When selecting T-bet positively regulated genes, the signal fold change
of T-bet-/- vs. WT, T-bet-/- vs. IFN-γ-/-, and IFN-γ-/- vs. WT is >4, >3 and <2, respectively, and the
lowest signal value limit of WT group is set at 1675 (210.71). When selecting T-bet negatively
regulated genes, the signal fold change of T-bet-/- vs. WT, T-bet-/- vs. IFN-γ-/-, and IFN-γ-/- vs.
WT is >2, >2 and <2, respectively, and the lowest signal value limit of T-bet-/- group is set at
1024 (210). In heat map scale, signal value of 1024 (210) was termed “0.00” and represented by
black color; signal value of 8192 (213) was termed “3.00” and represented by red color; signal
value of 128 (27) was termed “-3.00” and represented by green color. Mouse array data can be
accessed at ArrayExpress (http://www.ebi.ac.uk/arrayexpress/) under accession number EMTAB-2198.
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To quantify mRNA using real-time PCR, extracted total RNA was reverse transcribed to
cDNA using a High Capacity cDNA Reverse Transcription Kit. All PCR experiments were
performed using TaqMan gene expression assays (Hopx, Mm00558630_m1; Slamf1,
Mm00443316_m1; Serpinb9, Mm00777163_m1; Igf2r, Mm00439576_m1; Klrd1,
Mm00495182_m1; Klrc1, Mm00516111_m1; H-2Aa, Mm00439211_m1; H-2Ab1,
Mm00439216_m1; Retnla, Mm00445109_m1; GAPDH, Mm99999915_g1), universal PCR
Master Mix and the ABI-PRISM 7900 Sequence Detection System (Applied Biosystems, Life
technologies, Grand Island, NY). Target gene expression was calculated using the comparative
method for relative quantitation upon normalization to the internal GAPDH expression control.

2.3.5 In vitro generation of Th17 cells and Th17-mediated GVHD model
CD4+CD25- cells isolated from WT, T-bet-/- or IFN-γ-/- mice on B6 background were
stimulated in the presence of syngeneic APCs with 2 μg/mL anti-CD3 mAb, 5 ng/mL TGFβ, 10
ng/mL IL-6 and 5 μg/mL anti-IFN-γ mAb. On day 3, 50U/mL mIL-2 was added. Cell phenotype
(CD4+ IL-17+ %) was confirmed on day 4 by intracellular cytokine staining of IFN-γ and IL-17.
On day 5, polarized T cells were collected and dead cells were removed using Ficoll separation.
Equal numbers of live CD4+ IL-17+ cells derived from WT, T-bet-/- or IFN-γ-/- T cells were used
to induce GVHD to compare pathogenicity.

2.3.6 Statistics
For comparison of recipient survival among groups in GVHD experiments, the log-rank
test was used to determine statistical significance. To compare GVHD clinical scores, pathology
scores, weight loss, cytokine levels, and gene expression levels, a Student t test was used.
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2.4 Results

2.4.1 T-bet is required for CD4 T-cell mediated acute GVHD
Our previous study indicated that T-bet-/- total T cells are less pathogenic than their WT
counterparts in inducing GVHD in fully MHC-mismatched BMT models (47). In contrast, IFNγ, a major cytokine regulated by T-bet, is dispensable or even protective against GVHD
development (154-157, 287, 288). Considering Eomes is preferentially expressed on CD8 T
cells (32, 37) and CD4 T-cell differentiation is better defined (286, 296), we first focused our
studies on CD4-mediated GVHD and aimed to further understand how T-bet and IFN-γ
differentially affect the development of acute GVHD. As shown in figure 2.1, IFN-γ-/- CD4 T
cells mediated comparable GVHD to WT CD4 T cells, whereas T-bet-/- CD4 T cells caused
significantly milder GVHD. Recipients of T-bet-/- donor T cells showed significantly higher
long-term survival rates (Figure 2.1A), less weight loss (Figure 2.1B) and lower GVHD clinical
scores after 4 and 8 weeks following allo-BMT (Figure 2.1, C and D) compared with the
recipients of either WT or IFN-γ-/- CD4 T cells. Alleviated GVHD caused by T-bet-/- CD4 T cells
was also supported by significantly lower pathological scores of those recipients 14 days after
allo-BMT. Recipients of T-bet-/- CD4 T cells had markedly reduced T-cell infiltration and tissue
damage in GVHD target organs including the liver, gut, and skin (Figure 2.1, E and F). However,
T-bet-/- CD4 T cells induced similar severity of pulmonary GVHD as WT CD4 T cells (Figure
2.1, E and F), consistent with the previous report that pulmonary GVHD is not associated with
Th1-mediated response (297). Serum cytokines detected 14 days post-transplant revealed that Tbet-/- CD4 T cells produced significantly lower levels of IFN-γ compared to WT CD4 T cells
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Figure 2.1 T-bet is required for CD4 T-cell mediated acute GVHD. Lethally irradiated BALB/c
mice were transplanted with 5×106/mouse TCD-BM from WT B6 donor alone (n=7), or plus WT
(n=10), T-bet-/- (n=11), or IFN-γ-/- (n=10) CD4+ T cells at 1×106/mouse. Recipient mice were
monitored throughout the experimental period for survival (A), weight change (B), GVHD
clinical scores at 4 weeks (C) and 8 weeks (D) post-transplant. Lethally irradiated BALB/c mice
were transplanted with 5×106/mouse TCD-BM from WT B6 donor alone (n=4), or plus WT
(n=7), T-bet-/- (n=7), or IFN-γ-/- (n=8) naïve CD4+ T cells at 1×106/mouse. Recipients were
euthanized 14 days post-transplant and samples of liver, lung, small intestine, colon and skin
were collected for H&E staining (E) and scored for microscopic GVHD severity by a pathologist
blinded to the treatment groups. Photomicrographs depicting the average disease score
morphology from one representative experiment out of two separate experiments (Original
magnification ×200). Pathological score mean ± SE (F) of GVHD target organs across two
separate experiments are depicted. Sera collected at necropsy 14 days post-transplant were
subjected to cytokine bead analysis (G) to quantify serum cytokine concentrations of IFN-γ,
TNF-α, IL-6, and IL-10. Cytokines that were undetectable are not graphically represented. (H)
Recipients were euthanized 14 days post-transplant and samples of spleen and liver were
collected for intracellular staining of IL-17. FACS plots show CD4+IL-17+ cells from
representative recipients in each group. Data are shown from two replicate experiments
combined. Asterisk indicates statistical significance: *p<0.05, **p<0.01, ***p<0.001.
(Figure 2.1G). Consistent with the pathological scores, T-bet-/- CD4 T cells also produced lower
levels of TNF-α, but higher levels of IL-10 and IL-6 compared to either WT or IFN-γ-/- CD4 T
cells (Figure 2.1G). Furthermore, intracellular IL-17 expression was significantly higher in T-bet/-

or IFN-γ-/- donor T cells than in WT donor T cells in recipient spleens and livers (Figure 2.1H).

Altogether, T-bet deficient CD4 T cells produced lower levels of inflammatory cytokines and
induced less damage in the recipient liver, gut and skin, indicating that T-bet, not IFN-γ, is
required for CD4 T-cell mediated acute GVHD.

2.4.2 T-bet is important for GVHD induction in miHA-mismatched model
miHA mismatches play a critical role in clinical GVHD development in human leukocyte
antigen (HLA)-identical BMT conditions (298). Given the effect of T-bet-/- or IFN-γ-/- total T
cells in fully MHC-mismatched models has been reported previously by us and others (47, 288,
299), we utilized a clinically relevant MHC-matched, multiple miHA-mismatched CD450

dependent BMT model, B6→BALB.B, and found that the recipients which received splenocytes
from T-bet-/- mice demonstrated prolonged survival with decreased GVHD severity compared
with those that received WT or IFN-γ-/- splenocytes (Figure 2.2). These results suggested that Tbet plays a critical role in the development of acute GVHD regardless of BMT model.

Figure 2.2 T-bet is required for GVHD induction in miHA-mismatched BMT model.
Lethally irradiated BALB.B mice were transplanted with 5×106/mouse TCD-BM from WT B6
donor alone (n=6), or plus WT (n=9), T-bet-/- (n=11), or IFN-γ-/- (n=9) splenocytes (SP) at
20×106/mouse. Recipient mice were monitored throughout the experimental period for survival
(A) and weight change (B). Data are shown from two replicate experiments combined. Asterisk
indicates statistical significance: *p<0.05, **p<0.01, ***p<0.001.

2.4.3 Differential gene profiles of T-bet-/- and IFN-γ-/- CD4 T cells after allo-BMT
To determine the mechanism of how T-bet affects T-cell pathogenicity in the induction of
GVHD, we hypothesized that the molecules which are regulated by T-bet but not required for
IFN-γ production are responsible for GVHD development. To identify these molecules, we
isolated donor CD4 T cells from spleens of recipients at 7 days following allo-BMT
(B6→BALB/c) and analyzed the gene profiles by microarray. Internal controls, Tbx21 (gene
encoding T-bet) and Ifng (gene encoding IFN-γ), were essentially absent in T-bet-/- CD4 T cells
and IFN-γ-/- CD4 T cells, respectively (Figure 2.3, A and B). The microarray heat map showed
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that, a total of 28 genes were down-regulated and 8 genes were up-regulated only in T-bet-/- but
not in IFN-γ-/- CD4 T cells compared to WT CD4 T cells (Figure 2.3A). Among them, we chose
to present those genes potentially relevant to GVHD in a bar graph, including Cxcr3, Ccr5, Ccl3,
Ccl4, Klrc1, Klrd1, Nkg7, and Pdcd1 that were positively regulated, whereas H2-Aa and H2-Ab1
were negatively regulated by T-bet independent of endogenous IFN-γ (Figure 2.3B). Changes in
representative genes (Hopx, Slamf1, Serpinb9, Igf2r, Klrd1, Klrc1, H2-Aa, H2-Ab1 and Retnla)
were confirmed by real time PCR (Figure 2.3C). We reason that at least some of those genes we
identified are responsible for the compromised ability of T-bet-/-, not IFN-γ-/-, CD4 T cells in the
induction of GVHD.

Figure 2.3 Differential gene profiles of T-bet-/- and IFN-γ-/- CD4 T cells after allo-BMT.
Lethally irradiated BALB/c mice were transplanted with 5×106/mouse TCD-BM from WT
Ly5.1+ B6 donor plus WT, T-bet-/- or IFN-γ-/- naïve CD4+ Ly5.1- T cells at 1×106/mouse (n=4 per
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group per experiment). Recipients were euthanized 7 days post-transplant and their spleens were
collected. By sorting different strains of donor-derived T cells (CD4+ H-2Kb+ Ly5.1- DAPI-)
from recipient splenocytes, 1~2×106 cells were obtained per group, and total RNAs were
extracted for microarray and real-time PCR analysis. The genes shown are significantly changed
in the T-bet-/- group but not shared by the IFN-γ-/- group. Heat map (A), and mean signal value ±
SE (B) of representative genes identified by microarray using either WT, T-bet-/-, or IFN-γ-/donor CD4 T cells were shown. Selected gene expressions were confirmed by real-time PCR
(C). Pooled data from three independent experiments are presented. Asterisk indicates statistical
significance: **p<0.01, ***p<0.001.

2.4.4 T-bet regulates T-cell pathogenicity through IFN-γ-independent manners
Our microarray data provides potential explanations for why T-bet-/- and IFN-γ-/- T cells
induce distinct outcomes of GVHD at the gene level. However, protein expression is typically
better correlated with biological function. To confirm our microarray study and further
investigate the underlying mechanism, we utilized a MHC-mismatched BMT model
(B6→BALB/c), and examined the expression of several molecules, which represent multiple
aspects of allogeneic T-cell function: activation (I-Ab and NKG2D), migration (CXCR3),
cytotoxicity (CD94 and GZMB), and exhaustion (PD-1), of donor T cells by flow cytometry 7
days after allo-BMT. We observed that T-bet-/- donor T cells significantly impaired proliferation
in secondary lymphoid organs (spleen) and migration into target organs (liver), when compared
to their WT counterparts (Figure 2.4A). This was consistent with their significantly decreased
IFN-γ production, but increased IL-17 and IL-10 secretion (Figure 2.4B). T-bet-/- donor T cells
also showed significantly less infiltration into the liver compared with IFN-γ-/- T cells (Figure
2.4A). The expansion defect of T-bet-/- T cells in the spleen is mostly displayed in the CD8 but
not CD4 subpopulation (Figure 2.4A), which indicated that absence of T-bet affects multiple
aspects of CD4 T cell function independent of cell expansion. Moreover, in contrast to WT or
IFN-γ-/- T cells, T-bet-/- T cells significantly decreased the expression of CXCR3, NKG2D, PD-1,
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and CD94, but increased the expression of I-Ab and GZMB in CD4 or CD8 constituent
subpopulations (Table 2.1), or both (Figure 2.4C).

Figure 2.4 T-bet regulates T-cell migration and cytokine production through IFN-γ-independent
manners. Lethally irradiated BALB/c mice were transplanted with 5×106/mouse TCD-BM from
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WT Ly5.1+ B6 donor plus WT, T-bet-/-, IFN-γ-/- or IFN-γR-/- naïve CD4+ Ly5.1- T cells at
1×106/mouse (n=3~4 per group). Recipients were euthanized 7 days post-transplant and their
spleens and livers were collected and absolute numbers of donor total T cell, CD4+ or CD8+ T
cell were shown (A). Production of IFN-γ, IL-17 and IL-10, and expression of CXCR3, NKG2D,
I-Ab, PD-1, CD94 and granzyme B (GZMB) by WT, T-bet-/-, IFN-γ-/- or IFN-γR-/- donor T cell in
recipient spleen were shown in bar graph (B), and histograms (C), respectively. Data from one
representative experiment were presented. Asterisk indicates statistical significance: *p<0.05,
**p<0.01, ***p<0.001.
Table 2.1 Differential protein expression of T-bet-/- and IFN-γ-/- T cell after allo-BMT.
CD4

Mean ±
SD %

WT

-/-

T-bet

+

CD8
-/-

IFN-γ

-/-

IFN-γR

WT

-/-

T-bet

+
-/-

IFN-γ

-/-

IFN-γR

CXCR3 44.9±8.6 30.2±3.0 57.5±4.3 24.2±2.0

73.6±6.1 48.0±3.4 80.3±3.6 56.8±1.0

NKG2D 22.1±0.7 20.9±2.1 18.8±1.5 14.9±0.5

60.9±1.5 29.3±2.0 47.7±2.3 52.4±4.9

b

I-A

17.1±3.7 54.6±9.1 15.2±3.5 26.9±3.4

29.7±4.6 55.8±4.1 25.7±5.5 37.0±4.9

PD-1

15.5±2.5 12.0±1.8 17.0±4.5 5.9±1.0

43.4±5.7 30.9±3.0 62.3±7.3 24.3±5.4

CD94

10.3±0.8 2.4±1.3

3.3±0.8

2.6±1.3

26.4±0.8 4.9±1.1 35.6±3.6 34.0±5.7

1.6±0.6

1.8±1.0

2.0±0.4

0.6±0.4 3.0±2.1

GZMB

6.3±2.9

1.3±0.3

0.5±0.3

Given IFN-γ can be produced by other cell types besides donor T cells, we aimed to
distinguish the dependence of endogenous or systematic IFN-γ by including IFN-γR-/- T cells as
additional controls, which are able to produce IFN-γ (Figure 2.4B) but unable to respond to IFNγ. We found that CXCR3 and PD-1 were expressed in similarly low levels on the T cells
deficient for T-bet or IFN-γR, but not IFN-γ. This suggests that their protein expression depends
on T-bet, not endogenous IFN-γ, although it can be regulated by IFN-γ produced by other types
of cells in the recipient. On the other hand, the expression of NKG2D, CD94, I-Ab and GZMB
depends on T-bet, but not systematic IFN-γ, because their protein profiles are distinct on the T
cells deficient for T-bet versus either IFN-γ or IFN-γR. Therefore, we have identified several T-
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bet-dependent, but endogenous or systematic IFN-γ-independent molecules, that likely
contributed to the impaired target organ migration and Th1-cytokine production by T-bet-/- T
cells.

2.4.5 T-bet controls the optimal function of Th17 cells in GVHD induction
It is known that Th1-differentiation antagonizes Th17-differentiation (30, 300). Our data
shows that either T-bet-/- or IFN-γ-/- T cells are prone to differentiate into Th17 cells both in vitro
(Figure 2.5) and in vivo (Figure 2.1H), which is consistent with previous reports (47, 159).

Figure 2.5 T-cell differentiation from WT, T-bet-/- and IFN-γ-/- CD4 T cells in vitro. Isolated
CD4+ CD25- T cells (5×105) from WT, T-bet-/-, and IFN-γ-/- mice on B6 background were co-
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cultured with enriched CD11chigh (5×104) allogeneic bone marrow-derived dendritic cells (BMDCs) for 5 days and the difference in IFN-γ and IL-17 production were shown by FACS plots.

Given the Th17 subset, per se, is capable of causing GVHD (80, 81), we hypothesized that
optimal activity of Th17 cells may require T-bet but not IFN-γ, which may attribute to a distinct
pathogenicity of T-bet versus IFN-γ in GVHD induction. Therefore, we examined the role of Tbet or IFN-γ in the pathogenicity of Th17 cells to cause GVHD using optimized Th17-polarizing
culture conditions. We generated > 70% CD4+ IL-17+ cells from naïve CD4 T cells of WT, Tbet-/- or IFN-γ-/- B6 mice (Figure 2.6A) and then transferred equal numbers of these T cells into
lethally irradiated BALB/c recipients. We found that T-bet-/-, not IFN-γ-/-, Th17 cells had a
significantly reduced ability to induce GVHD. This is reflected by ameliorated morbidity and
mortality of the recipients (Figure 2.6, B and C). Because bone marrow stromal niche is
considered a sensitive target of allogeneic T cells, and the defective donor bone marrow-derived
B lymphopoiesis is correlated with GVHD severity (301), we examined the percentage of donorderived B cells at the end of observation periods (around day 85 after allo-BMT), which was
found to be significantly higher in the recipients of T-bet-/- Th17 cells than those of WT or IFN-γ/-

Th17 cells (Figure 2.6 E), despite a similar number of total splenocytes among these groups

(Figure 2.6 D). These data strongly suggest that T-bet also affects the pathogenicity of Th17 cells
in GVHD induction. Moreover, Th17 pathogenic and nonpathogenic signature molecules are
previously defined in autoimmune models, such as experimental autoimmune encephalomyelitis
(EAE) (302-304). Based on the similar requirement of Th1 and/or Th17 cells and on T-bet
expression in the induction of EAE and GVHD (47, 49), we used the genes identified in EAE
model as a reference, to indirectly reflect the effects of T-bet on regulating Th17 pathogenicity in
allo-BMT settings. Our microarray results indicate that T-bet positively regulated Th17
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pathogenic signature genes on CD4 T cells after allo-BMT, such as Lrmp, Ccl5, ICOS, Stat4,
Lgals3, Malt1 and GM-CSF, while negatively regulating Th17 nonpathogenic signature genes
such as IL-10 (Figure 2.7). The observation is in-line with our hypothesis that T-bet contributes
to the optimal function of Th17 cells after allo-BMT.

Figure 2.6 T-bet controls the optimal function of Th17 cells in GVHD induction. Lethally
irradiated BALB/c mice were transplanted with 5×106/mouse TCD-BM from WT B6 donor
alone (n=8), or plus in vitro polarized WT (n=12), T-bet-/- (n=17) or IFN-γ-/- (n=12) Th17 cells
(A) at 0.5~1×106 /mouse after normalization of IL-17 producing CD4+ cells. Recipient mice
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were monitored throughout the experimental period for survival (B) and weight change (C).
Upon completion of the experiment on day 80-90, absolute number (D) and percentage of donorderived B-cell (B220+) and T-cell (CD4+ or CD8+) reconstitution (E) of the spleen cells from
remaining recipients were analyzed. Pooled data from three independent experiments are
presented. Asterisk indicates statistical significance: *p<0.05, **p<0.01, ***p<0.001.

Figure 2.7 T-bet regulates Th17 pathogenic or nonpathogenic signature genes after allo-BMT.
Mean signal value ± SE of selected Th17 pathogenic or nonpathogenic genes including Lrmp,
Ccl5, ICOS, Stat4, Lgals3, Malt1, GM-CSF and IL-10, identified by microarray using either WT,
T-bet-/-, or IFN-γ-/- donor CD4 T cells 7 days post allo-BMT were shown. Pooled data from three
independent experiments are presented. Asterisk indicates statistical significance: *p<0.05,
**p<0.01, ***p<0.001.
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2.4.6 T-bet-/- donor T cells largely preserve the GVL effect by neutralizing IL-17 in
allo-BMT recipients
The ultimate goal of allo-HSCT is to prevent GVHD while preserving the GVL effect.
Cytotoxic CD8 T cells are known to play a predominate role in mediating GVL effects (265,
305). GVL effects of IFN-γ-/- T cells have been shown to correlate inversely with their GVHDinducing activity in a CD8-dependent model (157). We hypothesized that T-bet-/- T cells may
maintain their GVL activity due to the presence of Eomes, which preserves CD8 T-cell cytotoxic
activity (32, 33). We tested the expression of Eomes and IFN-γ on CD4 and CD8 T cells in the
presence or absence of T-bet and found that Eomes was mainly expressed on CD8 T cells
compared to CD4 T cells. T-bet-/- CD8 T cells highly expressed Eomes and maintained IFN-γ
production (Figure 2.8). To determine whether T-bet is required for T-cell mediated GVL effect,
we used a B6 → BALB/c BMT model and infused a low dose of A20-luc B-cell lymphoma on
the day of allo-BMT, which mimics clinical setting where a small number of malignant cells
survive in patients after pre-conditioning regimen. We found that WT T cells at 0.25~0.5 ×
106/mouse could effectively reject tumor, but the majority of recipients (79%) quickly died of
GVHD (Figure 2.9 A, B and C). However, the recipients of 0.25~0.5 × 106 T-bet-/- T cells
showed delayed tumor growth compared to those of BM alone, but eventually the majority of
these recipients (86%) died of tumor relapse (Figure 2.9 A, B and C). These data suggest that
although T-bet deficient T cells still express Eomes and had partially preserved ability to produce
IFN-γ, their GVL activity was largely compromised.
T cells deficient for T-bet produce elevated levels of IL-17 (Figure 2.1H and 2.4B).
Substantial evidence supports that IL-17 enhances tumor resistance to anti-angiogenesis therapy
(306), promoting tumor progression through an IL-6/Stat3 signaling pathway (307, 308). Our
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previous study indicates that additional RORγt (transcription factor of Th17 cells) deficiency
reverses the enhanced ability of T-bet-deficient T cells to produce IL-17. Furthermore, Tbet/RORγt-deficient T cells have largely preserved GVL activity (47). Therefore, we further
hypothesized that elevated IL-17 contributed to the compromised GVL effect of T-bet-/- T cells.
To test this, we used the same MHC-mismatched B6→BALB/c model with IL-17 neutralizing
mAb (clone: 17F3), and found that treatment with anti-IL-17 mAb significantly reduced tumor
relapse in the recipients of T-bet-/- T cells. This is reflected by improved survival (Figure 2.9A)
and reduction of tumor signal intensity by BLI (Figure 2.9 C and D). In contrast, the same
treatment did not affect the survival of the recipients transplanted with WT T cells. Our data
suggests that the compromised GVL activity of T-bet-/- T cells was, at least in part, due to
elevated IL-17 produced by these T cells.
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Figure 2.8 T-bet and Eomes expression on WT, T-bet-/- and IFN-γ-/- T cells in vitro. WT, T-bet-/or IFN-γ -/- splenocytes were harvested and stimulated with anti-CD3 Ab for 3 days. PMA and
ionomycin were added on day 3 to further stimulate the cells for intracellular staining of IFN-γ.
Expression of T-bet, Eomes and production of IFN-γ by CD4 or CD8 T cells were shown.
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Figure 2.9 T-bet-/- donor T cells largely preserve GVL effect upon neutralizing IL-17 in alloBMT recipients. BALB/c mice were lethally irradiated and transplanted with 5×106/mouse TCDBM from WT B6 donor alone, or plus WT or T-bet-/- purified T cells at 0.25~0.5×106/mouse.
Additionally, recipients were intravenously injected with 2×103/mouse A20 luciferasetransduced lymphoma cells at the time of BMT. Recipients were i.p. injected with α-IL-17 mAb
(500μg/mouse for first dose, and 200μg/mouse for the following doses) or PBS control for 4
weeks (at day 0, 3, 7, 10, 14, 18, 21, 25 and 28), and were monitored throughout the
experimental period for survival (A), weight change (B), and tumor growth by luciferin i.p.
injection and whole body BLI (n=4~7 per group per experiment). Recipient BLI image (C)
represents one of the 2 replicated experiments and average radiance intensity of BLI (D) pooled
from all experiments was shown. Asterisk indicates statistical significance: *p<0.05.

2.5 Discussion
Here we show that T-bet deficient donor T cells, in contrast to IFN-γ deficient donor T
cells, are impaired in their ability to induce acute GVHD in allogeneic recipients in fully MHCmismatched (Figure 2.1 and 2.6) or MHC-matched but miHA-mismatched (Figure 2.2) murine
BMT models. We identified distinct genetic profiles of T cells deficient for T-bet or IFN-γ to
account for this difference (Figure 2.3) and further elucidated several T-bet downstream
molecules, independent of either endogenous or systematic IFN-γ, contributed to GVHD
pathogenicity (Figure 2.4). Furthermore, we found that T-bet deficient donor T cells have
preserved GVL activity when the resulting increased IL-17 is neutralized (Figure 2.9).
Acute GVHD has been considered a Th1-type disease dominated by cytotoxic T cellmediated pathology and increased production of Th1-type cytokines, including IFN-γ (78, 152,
153). Our data indicates that T-bet is required for CD4 T-cell mediated GVHD by controlling
the differentiation and migration of Th1 cells (Figure 2.1) and the optimal function of Th17 cells
(Figure 2.6). T-bet-/- CD4 T cells produced significantly lower levels of the pathogenic cytokine
TNF-α, but higher levels of the anti-inflammatory cytokine IL-10 in recipient sera after adoptive
transfer, which lead to reduced tissue damage in the liver and gut, compared to either WT or
IFN-γ-/- CD4 T cells (Figure 2.1). Conversely, the Th17-related cytokine IL-6 was elevated in
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recipient sera if the donor CD4 T cells were T-bet-/- (Figure 2.1G). In addition, increased IL-17
production by T-bet-/- donor CD4 T cells was present in recipient spleens and livers (Figure
2.1H). Our previous study also indicates that T-bet-/- CD4 T cells produced higher levels of Th2related cytokines, IL-4 and IL-5, in recipient spleens, livers, and lungs (47). Consistent with
previous reports, donor CD4 T cells can reciprocally differentiate into Th1, Th2, and Th17 cells,
and each Th subset contributes to specific GVHD target organ tissue damage. Liver and gut are
the primary target organs for Th1 cells, and skin is the primary target organ for Th17 cells,
whereas pulmonary GVHD is mainly mediated by Th17 and Th2 cells (159). We observed that
T-bet-/- CD4 T cells induced severe pulmonary GVHD similar to WT counterparts (Figure 2.1, E
and F). We attribute the severe lung pathology mediated by T-bet-/- CD4 T cells to the
augmented Th2 and Th17 cells and to the minimal IFN-γ production which leads to decrased
PD-L1 expression on lung parenchyma (159). Moreover, due to the direct cytotoxicity of IFN-γ
to the gastrointestinal tract (156), absence of T-bet or IFN-γ in donor CD4 T cells induced
similar severity of colon GVHD but was less than that induced by WT CD4 T cells (Figure 2.1,
E and F).
Multiple preclinical studies have investigated a paradoxical protective role of IFN-γ in
GVHD development under lethal conditioning (154-157, 287, 288). In our current settings, IFNγ-/- T cell induced comparable, not more severe GVHD, as their WT counterparts, which is likely
due to the type and dose of donor T cells given was different from other studies (154-157, 287,
288). Taken together, the consensus is that IFN-γ produced by donor T cells is not required for
the development of acute GVHD after lethal TBI and allo-BMT. However, the current work
showed that T-bet, a transcriptional activator of IFN-γ, was required for GVHD induction. To
further define the underlying mechanisms, we identified the differential gene profiles of donor T
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cells deficient for T-bet or IFN-γ after allo-BMT. The potential key mediators include but are not
limited to the following genes: Cxcr3, Ccr5, Ccl3, Ccl4, Klrc1, Klrd1, Nkg7, Pdcd1, H2-Aa and
H2-Ab1 (Figure 2.3). These targets are either positively or negatively regulated by T-bet and
represent different aspects of allogeneic T-cell activity: activation (H2-Aa and H2-Ab1),
migration (Cxcr3, Ccr5, Ccl3, and Ccl4), cytotoxic function (Klrc1, Klrd1, and Nkg7) or
exhaustion (Pdcd1).
It is interesting that expression of MHC-II genes H2-Aa and H2-Ab1 were increased on
T-bet-/- CD4 T cells. The protein level of I-Ab (gene: H2-Ab1) was also significantly increased
in T-bet-/- T cells, compared to either WT, IFN-γ-/-, or IFN-γR-/- T cells (Figure 2.4C and Table
2.1), which we classified as a T-bet-dependent but systematic IFN-γ-independent molecule.
Given that transfer of MHC molecules from APCs to T cells does exist, and the MHC-IIexpressing T cells can engage in T: T interactions leading to increased apoptosis and
hyporesponsiveness (309, 310), it is possible that overexpression of MHC-II molecules (such as
I-Ab) on T-bet-/- donor T cells may result in increased cell death due to fratricide of allogeneic T
cells. Alternatively, those MHC-II-expressing T-bet-/- T cells may compete with professional
dendritic cells to present antigen, but not effectively induce T-cell proliferation due to lack of
costimulatory signals; the regulatory mechanism utilized by T-bet-NKp46-RORγt+ innate
lymphoid cells as demonstrated in a recent report (311).
Chemokine receptors and chemokines play important roles in T-cell migration to GVHD
target organs (312, 313). CXCR3 is a direct target of T-bet (117), and targeting CXCR3 using its
mAb can inhibit CD8-mediated GVHD in murine allo-BMT models (314). Targeting CCR5
using a small molecule inhibitor (Maraviroc) has recently been reported to be beneficial in
patients with visceral GVHD in early clinical trials (315). Additionally, gene expression of
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CCL3 and CCL4, ligands of CCR5 (316), were also found to be positively regulated by T-bet.
Our data further indicates that CXCR3 is likely one of the key effectors contributing to the
severe GVHD caused by IFN-γ-/- but not T-bet-/- T cells (Figure 2.1); in that the presence of
systematic IFN-γ preserves the high expression of CXCR3 in IFN-γ-/- T cells via IFN-γR
signaling, which was significantly reduced in T-bet-/- T cells at the gene level (Figure 2.10). This
was also consistent with previous reports that the addition of exogenous IFN-γ to cultures of
IFN-γ-/- T effector cells rescued CXCR3 expression (299). Therefore, in contrast to WT or IFN-γ/-

T cells, T-bet-/- T cells expressed significantly lower levels of Th1-related chemokine receptor

genes (Cxcr3 and Ccr5) and chemokine genes (Ccl3 and Ccl4), as well as the CXCR3 protein.
This impedes the migration and infiltration of allogeneic T cells to GVHD target organs (Figure
2.1 and 2.4).
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Figure 2.10 Gene profiles of IFN-γR identified by microarray. Mean signal value ± SE of genes
Ifngr1 and Ifngr2 identified by microarray using either WT, T-bet-/-, or IFN-γ-/- donor CD4 T
cells 7 days post allo-BMT were shown. Pooled data from three independent experiments are
represented. Asterisk indicates statistical significance: ***p<0.001.
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Administration of an agonistic mAb of NKG2A inhibited donor T cell expansion and
ameliorated acute GVHD in mice (317). However, we show that T-bet-/- donor T cells express
extremely low levels of CD94/NKG2A genes (Klrd1and Klrc1, respectively) (Figure 2.3), and
CD94 protein (Figure 2.4), in concert with ameliorated GVHD, suggesting that CD94/NKG2A
could be biomarkers to positively predict GVHD severity. Lower expression levels of inhibitory
molecules CD94, NKG2A, and T cell exhaustion marker PD-1 (Figure 2.3 and 2.4), on the other
hand, may suggest that T-bet-/- T cells can still preserve their cytotoxic function to overcome
tumor growth, which was additionally supported by enhanced production of GZMB by T cells
deficient for T-bet but not IFN-γ (Figure 2.4C). Nkg7, a promoter of the T and NK cell surface
cytotoxic molecule (318), has been considered as a Th1 cell-specific gene of which expression
was previously shown to be regulated by T-bet (20, 117), and is positively correlated to cytotoxic
T-cell destruction of epidermal cells in human GVHD (319).
In murine EAE models, deficiency in IFN-γ leads to exacerbated disease (320, 321).
However, T-bet-deficient mice are protected from developing EAE (49, 50). We have observed
similar results in GVHD models, which suggest that silencing Tbx21 has therapeutic potential.
Because transcription factors are difficult to be pharmacologically targeted, an alternative
approach is targeting T-bet downstream molecules that are independent of endogenous or
systematic IFN-γ (Figure 2.4), such as NKG2D, which is expressed on a variety of immune cells
and plays a costimulatory role in activating CD8 T cells (322). Indeed, we classified NKG2D as
a T-bet-dependent but systematic IFN-γ-independent molecule (Figure 2.4), consistent with the
unpublished data from us and others (323), which indicates that blockade of NKG2D alleviated
GVHD induced by CD8 or total T cells.
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Th17 cells are capable of inducing GVHD in mice (80, 81). Both T-bet-/- and IFN-γ-/CD4 T cells are prone to Th17-differentiation with high levels of IL-17 production (Figure 2.5).
In contrast to in vitro polarized WT or IFN-γ-/- Th17 T cells, T-bet-/- Th17 cells caused very mild
GVHD (Figure 2.6, B-E). Consistently, our microarray data reveals that T-bet controls the
optimal function of Th17 cells in GVHD possibly through regulating the expression of multiple
genes representing Th17 pathogenic or nonpathogenic signatures (Figure 2.7). Our study showed
T-bet-/- and IFN-γ-/- CD4 T cells have similar expression patterns of IFN-γ and IL-17 but
opposing GVHD severities, which indicated that the culprit for GVHD development may not be
IFN-γ or IL-17, but likely downstream effectors of T-bet we identified.
Although IL-17 seems to have less effect on GVHD development, it influences the tumor
microenvironment, especially when shielding the GVL response of T-bet deficient donor T cells
(Figure 2.9). T-bet-/- T cells produce more IL-17 than WT T cells (Figure 2.1H and 2.5), and IL17 promotes tumor progression in a variety of tumors (306-308). Consistently, neutralizing IL-17
benefits overall survival of recipients transplanted with T-bet-/-, not WT T cells. However, the
GVL preservation of T-bet-/- T cells is reduced after stopping anti-IL-17 treatment. The tumor
gradually relapsed, which further supports the detrimental role of IL-17 against preserved GVL
effects of T-bet-/- T cells. We conclude that T-bet deficient T cells induce less GVHD and may
still preserve GVL effects if the elevated levels of IL-17 are reversed. This is also supported by
our previous findings that double deficiency of T-bet and RORγt prevents GVHD while sparing
the GVL effect (47). Targeting T-bet itself is still far from translational application due to a lack
of a specific inhibitor. Recently, the small molecule inhibitors for other transcription factors,
such as c-Rel and RORγt, have been developed and showed promising results in alleviating
GVHD (324) or cutaneous inflammatory disorders (325), respectively. The c-Rel inhibitor also
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permits the maintenance of the GVL effect. Once T-bet inhibitors are developed, the mechanism
we defined in the current study together with our previous report (47) will become applicable,
e.g. a combinational treatment of T-bet inhibitor and anti-IL-17 mAb may be beneficial in
controlling GVHD while maintaining the GVL effect.
Collectively, using genetic knockout mice, we prove that T-bet is critical for the
development of aGVHD through controlling the differentiation and migration of Th1 cells as
well as the pathogenicity of Th17 cells. Given that T-bet is a transcription factor which is
unavailable to be pharmacologically targeted currently, we identify potential molecular targets
downstream of T-bet, and define the underlying mechanisms accounting for the distinct GVHD
outcomes caused by T-bet-versus IFN-γ-deficient donor T cells. This provides the rationale to
target those T-bet-dependent, but endogenous or systematic IFN-γ-independent molecules, for
the control of aGVHD in clinical settings.
In the study presented in Chapter 2, we investigated the effect and mechanism of T-bet in
regulating T cell activity and function in the development of aGVHD after allo-BMT.
Pharmacological blockade of T-bet, once available, is expected to affect other cell compartments
in addition to donor T cells as far as they express T-bet. Because APCs also express T-bet and
play critical roles in the induction of aGVHD, we therefore studied how T-bet regulates APC
functions in mediating aGVHD and GVL effect, and we will report our findings in the next
chapter.
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Chapter 3: T-bet Promotes Acute Graft-versus-Host Disease by Regulating Hematopoietic
Antigen Presenting Cells in Mice

3.1 Abstract3
Beyond its critical role in T cells, T-bet regulates the functions of APCs including DCs
and B cells. Given that APCs are essential for priming allogeneic T cells and the development of
GVHD, we evaluated the role of T-bet on APCs in acute GVHD using murine models of alloBMT. The recipients deficient for T-bet developed much milder GVHD than their WT
counterparts in MHC-mismatched or CD4-depedent miHA-mismatched models. As the
functional readout of APCs, allogeneic donor T cells, in particular CD4 subset, significantly
reduced IFN-γ production, proliferation and migration, and caused less damage in liver and gut
in T-bet-/- recipients. We further observed that T-bet on recipient hematopoietic APCs was
primarily responsible for the donor T-cell response and pathogenicity in GVHD, while T-bet also
contributes to the function of donor hematopoietic APCs. T-bet-/- DCs, the most potent
hematopoietic APCs, produced less IFN-γ and expressed higher levels of Trail, but not FasL or
TNF, to induce significantly higher levels of apoptosis on donor T cells prior to their massive
proliferation. In fact, Trail/DR5 interactions served as a major signaling pathway responsible for
donor T-cell apoptosis and impaired GVHD development in the recipients deficient for T-bet.
Furthermore, while T-bet on hematopoietic APCs was required for GVHD development, it was
This abstract have been previously published (Fu et al. 56th ASH Annual Meeting, Blood, 2014,
124 (21), 846-846.) and are utilized with permission of the publisher (p132).
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largely dispensable for the GVL effect. Taken together with our previous findings, we propose
that T-bet is a potential therapeutic target for the control of GVHD through regulating T cells as
well as APCs.

3.2 Introduction
GVHD remains to be a major obstacle for the efficacy and continuing success of alloHSCT in the treatment of various malignant and non-malignant diseases (63). Activation of
antigen presenting cells (APCs) plays a crucial role in priming alloreactive donor T cells to
induce and intensify GVHD (149, 221, 239, 240). After conditioning, temporarily survived
recipient APCs are essential for aGVHD initiation, especially in MHC-mismatched transplants
and in CD8-mediated aGVHD across only miHAs (68). Donor APCs also contribute to the
increased intensity of aGVHD by priming donor T cells (239, 240), and may perpetuate cGVHD
(238). APCs include diverse types of cells that have the common ability to prime T cells, such as
DCs, B cells and macrophages derived from the hematopoietic system. Hematopoietic APCs
clearly contribute to the development of GVHD (221), although recently have been proved
dispensable since recipient nonhematopoietic APCs, such as myofibroblasts, endothelial cells,
and epithelial cells, are sufficient to induce lethal GVHD in mice (249, 250). Among all APCs,
DCs are considered as the most efficacious APCs and potent inducers of GVHD due to their
superior ability to take up antigen, express co-stimulatory molecules, and produce
proinflammatory cytokines to polarize T cells (233, 326).
Our group and others previously reported the fundamental role of the T-box transcription
factor T-bet on T cells in GVHD, inflammatory diseases or autoimmune diseases (46, 47, 49, 54,
327). T-bet also regulates the activation and function of many APCs, such as DCs (4, 5, 58) and
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B cells (41, 328). Although the development, differentiation and activation of bone marrow
derived DCs and splenic DCs were unimpaired in mice lacking T-bet, T-bet is required for
optimal production of IFN-γ and antigen-specific T-cell activation by DCs (5), which is highly
correlated with GVHD induction. The study showed that T-bet-/- DCs failed to induce
inflammatory arthritis due to the compromised ability to secrete proinflammatory mediators and
to prime naive T cells (58). However, microbiome-dependent spontaneous colitis can occur in
the absence of T-bet as a result of the derepression of TNF-α in mucosal DCs (329). Therefore,
the effect of T-bet on DCs in the development of different diseases may depend on the
differential microenvironment.
In the current study, by using several well-defined, clinically relevant murine models of
allo-BMT, we found that T-bet deficiency on hematopoietic APCs, both recipient and donor
origin, attenuates aGVHD. The proliferation and IFN-γ production of allogeneic donor T cells
were significantly impaired in T-bet-/- recipients, but more Foxp3+ Tregs were present in their
spleens. Additionally, T-bet-/- APCs enhanced early apoptosis of allogeneic donor T cells within
lymphoid organs primarily through the Trail-DR5 axis, thus contributing to their decreased
infiltration and tissue damage to GVHD target organs. Furthermore, allogeneic donor T cells in
T-bet-/- recipients largely preserved GVL effect. Our data demonstrate T-bet is a promising
therapeutic target for the control of GVHD through regulating APCs functions.

3.3 Materials and methods
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3.3.1 Mice
C57BL/6 (B6; H-2b), congenic B6.Ly5.1+ (CD45.1+; H-2b), and FVB/N (FVB; H-2q)
were purchased from National Cancer Institute. 129S2/Sv (H-2b) were purchased from Charles
River Laboratories. T-bet-/- mice on B6 or BALB/c (H-2d) background, and C3H.SW (H-2b)
were purchased from The Jackson Laboratory. All animals were housed in the American
Association for Laboratory Animal Care–accredited Animal Resource Center at H. Lee Moffitt
Cancer Center or Medical University of South Carolina (MUSC). Experiments were carried out
under protocols approved by the Institutional Animal Care and Use Committee of University of
South Florida or MUSC.

3.3.2 BMT models
T-cell purification from whole spleen and lymph nodes was done by negative depletion
using magnetic beads as previously described (47). MHC- and miHA-mismatched (FVB→ B6;
B6→BALB/c) or MHC-matched but miHA-mismatched (129S2/Sv→ B6; C3H.SW→ B6) BMT
models were used as previously established (46, 289). Briefly, different strains of recipient mice
were conditioned with a lethal dose of total body irradiation (TBI). Within 24 hours postconditioning, recipients were i.v. injected with T-cell depleted (TCD)-BM alone or plus various
numbers of T cells purified from donor mice. Recipients were monitored for weight loss and
other clinical signs of GVHD twice/week (163). Spleens of DR5-/- mice on B6 background and
their wild type (WT) counterparts were kindly provided by Dr. Niklas Finnberg from Penn State
Hershey Cancer Institute. H&E staining and a semi-quantitative scoring system were used to
account for histologic changes consistent with GVHD in the target organs as previously
described (46, 47, 291).
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3.3.3 Chimeras BMT model
WT-B6 Ly5.1+ or T-bet-/- B6 mice were lethally irradiated with 1000-1200 cGy and
infused with TCD-BM cells from syngeneic T-bet-/- B6 or WT-B6 Ly5.1+ donors such that T-bet
deficiency is confined to only the hematopoietic cells or the nonhematopoietic cell
compartments, respectively. Control chimeras were also established by using lethally irradiated
WT-B6 Ly5.1+ or the T-bet-/- B6 mice as recipients, and transferred with TCD-BM cells from
syngeneic WT or T-bet-/- B6 donors respectively. Chimerism analyses of the donor
hematopoietic cells were complete donor types (>95%) 2-3 months after first syngeneic BMT
(data not shown). The [B6→ B6 Ly5.1+], [B6 T-bet-/- → B6 T-bet-/-], [B6 T-bet-/- → B6 Ly5.1+]
and [B6 Ly5.1+ → B6 T-bet-/-] mice were then used as recipients in an allo-BMT. The chimeric
mice received 1000-1200 cGy irradiations and were i.v. injected with purified T cells along with
TCD-BM cells from allogeneic FVB donors.

3.3.4 GVL model
In the B6→BALB/c model, recipients received 2×103 luc/neo plasmid-transduced A20 Bcell lymphoma cells (A20-luc) on BALB/c background, while in the FVB→B6 model, recipients
received 0.1×106 C1498 luciferase transduced atypical myeloid leukemia cells (C1498-luc)
generated in B6 mice at the time of BMT. Tumor mortality and GVHD mortality were
distinguished by BLI signal intensity and clinical manifestation of GVHD (46, 291).
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3.3.5 Flow cytometry
Mononuclear cells were isolated from recipient spleen and liver and stained and analyzed
for surface receptors and intracellular cytokines using standard flow cytometric protocols as
previously described (47, 291, 292).

3.3.6 In vivo mixed lymphocyte reaction (MLR)
T cells isolated from donor mice were gently mixed and incubated with 2 μM CFSE in
PBS at 37°C for 7 minutes. The CFSE-labeled T cells were i.v. injected into lethally irradiated
recipients. After 4 days, recipient splenocytes were stained and analyzed using flow cytometry.
Soluble DR5 (sDR5) protein is a human truncated DR5, which has been shown to effectively
block Trail induced apoptosis in both human and mouse systems (330). sDR5 used in certain
experiments was kindly provided by Dr. Youhai Chen from University of Pennsylvania.

3.3.7 Statistics
For comparison of recipient survival or tumor relapse rate, the log-rank test was used to
determine statistical significance (p<0.05). To compare GVHD clinical scores, pathology scores,
weight loss, cytokine levels, as well as in vivo and in vitro T-cell proliferation, a Student t test
was used.

3.4 Results
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3.4.1 T-bet expressed on host contributes to aGVHD
Development of GVHD is initiated by host APCs in presenting alloantigens to activate
donor T cells (286). To determine the effect of T-bet on host APCs in vivo, we utilized a fully
MHC-mismatched model (FVB→B6) of allo-BMT, where host APCs are essential for GVHD
development (68). Compared to WT, T-bet-/- recipients demonstrated significantly lower
mortality from GVHD after allo-BMT (Figure 3.1A) with less weight loss (Figure 3.1B), and
displayed significantly better donor-derived B220+ B-cell and CD4 and CD8 T-cell
reconstitution in spleen 80 days post-transplant (Figure 3.1, C-F). Because GVHD impairs donor
B- and T-cell reconstitution, these results reflect that T-bet-/- recipients suffered only mild
GVHD. The reduced mortality of T-bet-/- recipients was associated with less severe pathologic
injuries in liver and gastrointestinal (GI) tract on day 14 post-transplant as compared with their
WT counterparts. T-bet-/- recipients showed better maintenance of normal cell morphology in
GVHD target organs without severe lymphocyte infiltration (Figure 3.1, G and H). Thus, T-bet
expression in the host contributes to GVHD, suggesting a potential role of T-bet in regulating
recipient APCs.
3.4.2 T-bet on host determines alloresponse and impairs early apoptosis of
allogeneic donor T cells
APCs may affect the pathogenicity of donor T cells after allo-BMT in various ways,
including alloreactivity, homeostasis, and/or migration. We next evaluated these aspects as the
indirect functional readout of host APCs to understand the cellular mechanisms by which T-bet
regulates GVHD through host APCs. Donor CD4 and CD8 T cells showed significantly reduced
proliferation (CFSE staining) and activation (IFN-γ production) in T-bet-/- as compared to WT
allogeneic recipients, in which more defects were observed in CD4 than CD8 T cells (Figure 3.2,
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Figure 3.1 Absence of T-bet expression on host ameliorates GVHD. Lethally irradiated WT or
T-bet-/- mice on B6 background (n=9~15 per group) were transplanted with 5×106/mouse TCDBM from FVB donors alone, or plus purified FVB T cells at 2×106/mouse. Recipient mice were
monitored throughout the experimental period for survival (A) and weight change (B) posttransplant. Upon completion of the experiment on day 80, phenotypes of the spleen cells from
survived recipients were analyzed. Expression of H-2Kq, B220, CD4 and CD8 was detected by
flow cytometry and absolute number of total splenocytes (C), donor-derived B cells (D), CD4
(E) and CD8 (F) T cells were calculated. Pooled data from three separate experiments are
presented. In separate experiments with the same setting as A-E, recipients were euthanized 14
days post-transplant and samples of liver, lung, small intestine, large intestine, and skin were
collected for H&E staining and scored for microscopic GVHD severity by a pathologist blinded
to the treatment groups (G). Photomicrographs depict the average disease score morphology
from one representative experiment (n=3~4 per group). Pathological score mean ± SE of GVHD
target organs are depicted (H). Asterisk indicates statistical significance: *p<0.05, **p<0.01,
***p<0.001.
A-C). In those allogeneic recipients, absolute numbers of donor T cells (H-2Kq+) and CD4 T
cells were significantly reduced in the T-bet-/- recipients compared to the WT counterparts,
whereas the number of donor CD8 T cells were comparable (Figure 3.2 D). The impact of T-bet
on APCs specific to T-cell proliferation and activation was dependent on alloantigen recognition
because such an impact on T cells was not seen in syngeneic recipients (Figure 3.3A). We also
noticed that apoptosis (Annexin V+) was significantly increased in CD4 and CD8 donor T cells
in allogeneic T-bet-/- vs. WT recipients among CFSEhigh but not CFSElow population (Figure 3.2 E
and F). No difference in apoptosis of donor T cells was seen in syngeneic recipients regardless
of T-bet expression (Figure 3.3B). Collectively, these data suggest that the deficiency of T-bet on
host APCs mitigates allogeneic T-cell proliferation and IFN-γ production while enhancing
apoptosis before they undergo massive expansion.
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Figure 3.2 Allogeneic donor T cells significantly reduce IFN-γ production and proliferation but
increase early apoptosis in T-bet-/- recipients. WT or T-bet-/- B6 mice were lethally irradiated and
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transplanted with 3×106/mouse purified CFSE-labeled T cells from FVB donors (n=10 per
group, pooled from three experiments). Profiles of CFSE and IFN-γ in donor CD4+ or CD8+ T
cells were shown from representative recipients in each group 4 days post-transplant (A).
Percentages of CFSElow (B) and CFSElow IFN-γ+ donor T cells (C) are shown, and the absolute
numbers of total splenocytes, H-2Kq+, CD4+ or CD8+ T cells are presented (D). Profiles of CFSE
and Annexin V in donor CD4 or CD8 T cells are shown from representative recipients in each
group (E). Percentages of total T-cell apoptosis in CFSElow or CFSEhigh population are shown
(F). Asterisk indicates statistical significance: *p<0.05, **p<0.01, ***p<0.001.

3.4.3 T-bet expressed on host promotes donor CD4 T-cell accumulation in spleen
and infiltration to liver
To delineate allogeneic donor T-cell expansion and migration capacity, we utilized
congenic marker Ly5.1 to distinguish the donor T cells (Ly5.2+) from donor BM cells (Ly5.1+).
We found that, 7 days post-transplant, T-bet-/- recipients had higher numbers of total splenocytes,
but significantly decreased percentage of H-2Kb+ Ly5.2+ donor T cells, resulting in the
comparable absolute number of donor T cells in the spleens of WT and T-bet-/- recipients (Figure
3.4 A and C).
However, in T-bet-/- recipients, there were significantly fewer total CD4 donor T cells
(Figure 3.4C) which also produced less IFN-γ (Figure 3.4D) or expressed lower CXCR3 (Figure
3.4E), while recruiting significantly more CD25+Foxp3+ Tregs in the spleen compared to WT
recipients (Figure 3.4 B and C). Moreover, fewer total and IFN-γ-producing donor CD4 T cells
were detected in the liver of T-bet-/- recipients (Figure 3.4 G and H). On the other hand, no
significant differences in absolute number were observed on donor CD8 T cells in either the
spleens or livers of T-bet-/- vs. WT recipients (Figure 3.4 C-E, G and H). Therefore, we conclude
that increased expansion and/or generation of Tregs but decreased expansion and infiltration of
CD4 effector T cells were likely accounted for attenuated GVHD in T-bet-/- recipients (Figure
3.1).
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Figure 3.3 T-bet expressed on host is dispensable for activation, proliferation, and apoptosis of
donor T cells in syngeneic recipients. WT or T-bet-/- B6 mice were lethally irradiated and
transplanted with 3×106/mouse purified CFSE-labeled T cells from WT B6 donors (n= 3 per
group). Profiles of CFSE and IFN-γ (A), and CFSE vs. Annexin V (B) in donor CD4 or CD8 T
cells are shown from representative recipients in each group 4 days post-transplant.
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Figure 3.4 Allogeneic donor T cells significantly decrease accumulation in spleen and
infiltration to liver in T-bet-/- recipients. Lethally irradiated WT or T-bet-/- mice on BALB/c
background (n=9~10 per group, pooled from two experiments) were transplanted with
5×106/mouse TCD-BM from Ly5.1+ B6 donor alone, or plus 0.25×106/mouse purified Ly5.2+ T
cells from B6 mice. Seven days post-transplant, mononuclear cells were isolated from recipient
spleens and livers. Percentages of Ly5.2+ H-2Kb+ T cells (A) or CD25+Foxp3+ Tregs (B), and
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their CD4 and CD8 subpopulation in spleen are shown. Absolute numbers of total splenocytes,
total donor, CD4 or CD8 T cells and CD25+Foxp3+ Tregs in spleen are presented (C). Absolute
numbers of the donor CD4 or CD8 T cells producing IFN-γ (D) or expressing CXCR3 (E) in
spleen are presented. Percentages (F) and absolute number (G) of liver Ly5.2+ H-2Kb+ T cells
and their CD4 and CD8 subpopulation are shown. Absolute numbers of IFN-γ-producing donor
CD4 or CD8 T cells in liver (H) are presented. Asterisk indicates statistical significance:
*p<0.05, **p<0.01, ***p<0.001.

3.4.4 T-bet expressed on host contributes to GVHD in CD4 but not CD8-dependent
miHA-mismatched model
In addition to the MHC-mismatched models, we also evaluated the effect of T-bet on
APCs using more clinically relevant MHC-matched but miHA-mismatched models. Given
previous findings which demonstrated that APCs derived from the host, rather than from the
donor, are critical in inducing GVHD across miHA mismatch (218), we conditioned WT or Tbet-/- B6 recipients by TBI and transferred purified T cells from either 129S2/Sv or C3H.SW
donors, representing the CD4- or CD8-dependent miHA-mismatched model, respectively (123,
218, 331). In 129S2/Sv → B6 model, WT recipients exhibited 100% lethality with severe
clinical signs of GVHD, including weight loss, hunched posture, impaired mobility, ruffled fur,
and skin lesions, whereas T-bet-/- recipients only showed mild GVHD with low mortality and
morbidity (Figure 3.5 A-C). Distinct from the CD4-dependent model, in C3H.SW→ B6 model,
no significant difference in survival, body weight change, or clinical scores was observed in WT
versus T-bet-/- recipients (Figure 3.5 D-F). These data are consistent with those observed in
MHC-mismatched model that T-bet on the host primarily impacts CD4 rather than CD8 donor T
cells (Figure 3.2 and 3.4).
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Figure 3.5 Absence of T-bet expression on host ameliorates GVHD in CD4- not CD8-depedent
miHA-mismatched BMT model. Lethally irradiated WT or T-bet-/- mice on B6 background (n=6
per group) were transplanted with 5×106/mouse TCD-BM from 129S2/Sv donors alone, or plus
purified 129S2/Sv T cells at 10×106/mouse. Recipient mice were monitored throughout the
experimental period for survival (A), weight change (B), and GVHD clinical scores (C) posttransplant. Data from one representative experiment are presented. Lethally irradiated WT or Tbet-/- B6 mice (n=10~11 per group) were transplanted with 5×106/mouse TCD-BM from
C3H.SW donors alone, or plus purified C3H.SW CD44-CD25- T cells at 3×106/mouse. Recipient
mice were monitored throughout the experimental period for survival (D), weight change (E),
and GVHD clinical scores (F) post-transplant. Data pooled from two independent experiments
are presented. Asterisk indicates statistical significance between WT and T-bet-/- recipients given
T cell transfer: *p<0.05, **p<0.01, ***p<0.001.
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3.4.5 T-bet on host hematopoietic cells is primarily responsible for promoting
GVHD
Given both hematopoietic and nonhematopoietic APCs are known to contribute to the
development of GVHD (233, 249), we next evaluated the role of T-bet expression on either
population in mediating GVHD by using established BM chimeric mice as recipients. Severe
GVHD with < 20% long-term survival was induced in [B6→ B6 Ly5.1+] and [B6 Ly5.1+→ B6
T-bet-/-] chimeras in which T-bet was intact in their hematopoietic system, whereas mild GVHD
with > 70% long term survival was observed in [B6 T-bet-/- → B6 T-bet-/-] and [B6 T-bet-/- →
B6 Ly5.1+] chimeras in which T-bet was absent in their hematopoietic system (Figure 3.6).
These results demonstrate that T-bet on recipient hematopoietic APCs plays an essential role in
initiating GVHD, although the contribution of T-bet on nonhematopoietic APCs cannot be ruled
out as a delayed lethality was observed in [B6 Ly5.1+→ B6 T-bet-/-] chimeras as compared to
[B6→ B6 Ly5.1+] chimeras (Figure 3.6).
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Figure 3.6 T-bet is critical for recipient hematopoietic APCs to induce GVHD. Lethally
irradiated WT or four different types of chimeras ([B6→ B6 Ly5.1+], [B6 T-bet-/- → B6 T-bet-/-],
[B6 T-bet-/- → B6 Ly5.1+] and [B6 Ly5.1+ → B6 T-bet-/-]) on B6 background (n=5~11 per
group) were transplanted with 5×106/mouse TCD-BM alone or plus 2×106/mouse purified T
cells from FVB donors. Recipient mice were monitored throughout the experimental period for
survival (A) and weight change (B) post-transplant. Pooled data from two separate experiments
are presented. Asterisk in the legend indicates statistical significance regards survival curves:
*p<0.05, ***p<0.001.

3.4.6 T-bet regulates antigen presenting ability of donor hematopoietic APCs to
induce GVHD
Because donor APCs also contribute to priming allogeneic T cells, we evaluated the
effect of T-bet on donor APCs in the induction of GVHD. To reduce the contribution of
recipient APCs, we lethally irradiated BALB/c mice and reconstituted recipients with TCD-BM
cells from WT or T-bet-/- B6 donors 4 days prior to transferring allogeneic T cells. As expected,
the recipients of TCD-BM cells alone from either WT or T-bet-/- donors survived long-term
without GVHD. Additional allogeneic T cells induced more severe GVHD in the recipients that
were reconstituted with WT BM than those with T-bet-/- BM, reflected by survival, weight loss,
and clinical scores (Figure 3.7). These results indicate that T-bet also contributes to the antigen
presenting ability of donor hematopoietic APCs to induce GVHD.

3.4.7 T-bet-/- host DCs produce less IFN-γ and induce early apoptosis of donor T
cells primarily through Trail/DR5 axis
Hematopoietic APCs including DCs, B cells and macrophages that are capable of
priming donor T cells, but host DCs rather than host B cells are critical in the induction of CD4
or to a lesser extent CD8 T cell-dependent GVHD (243). Given T-bet does not express on
murine macrophages (5), we thus subsequently focused on host DCs, the most potent
86

professional APCs, and intended to understand how T-bet on host DCs modulates T-cell
responses after allo-BMT. Consistent with the previous study (5), we found that T-bet-/- DCs
expressed similar levels of MHC-II, CD86 and CD40 on day 4 post-transplant (data not shown),
but they produced significantly less IFN-γ compared with WT DCs during the interaction with
allogeneic, but not syngeneic T cells (Figure 3.8A). Additionally, T-bet-/- DCs expressed higher
levels of Trail, but not FasL or TNF-α, in allogeneic recipients (Figure 3.8B), although the
expression level of Trail receptor DR5 on donor T cells was comparable in either WT or T-bet-/recipients (Figure 3.9A). It is worth noting that CD4 T cells expressed higher levels of DR5 than
CD8 T cells especially among CFSEhigh population in the recipients regardless of T-bet
expression (Figure 3.9B).
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Figure 3.7 Donor hematopoietic APCs deficient for T-bet induce attenuated GVHD. Lethally
irradiated BALB/c mice (n=5~10 per group, pooled from two experiments) were transplanted
with 5×106/mouse TCD-BM alone from WT or T-bet-/- B6 mice on day 0, or plus additional
purified T cells from WT B6 mice at 1×106/mouse 3 days later. Recipient mice were monitored
throughout the experimental period for survival (A), weight change (B) and clinical scores (C)
post-transplant. Asterisk indicates statistical significance between WT and T-bet-/- recipients
given T cell transfer: *p<0.05, **p<0.01, ***p<0.001.

Figure 3.8 T-bet-/- host DCs induce early apoptosis of donor T cells primarily through Trail-DR5
pathway. WT or T-bet-/- B6 mice (n=3~4 per group, data from one representative experiment)
were lethally irradiated and transplanted with 3×106/mouse purified CFSE-labeled T cells from
WT B6 (syngeneic) or FVB donors (allogeneic). Production of IFN-γ (A) in host CD11c+ DCs
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was shown from representative recipients in each group 4 days post-transplant. In allogeneic
model, histogram of Trail, FasL and TNF-α with mean fluorescent intensity (MFI) are shown (B)
on gated CD11c+ cells. WT or T-bet-/- B6 mice (n=3 per group) were lethally irradiated and
transplanted with 3×106/mouse purified CFSE-labeled T cells from FVB donors. Recipients were
i.p. injected with either PBS control or sDR5 at 100µg/mouse on day 0, and 50µg/mouse on day
1, 2, and 3. Four days post-transplant, absolute numbers (C) of total donor CD4 or CD8 T cells
and percentage (D) of AnnexinV+ T cells in CFSEhigh or CFSElow population in spleen were
shown. Lethally irradiated WT or T-bet-/- BALB/c mice (n=5~6 per group) were transplanted
with 5×106/mouse TCD-BM from WT B6 donor alone, or plus 1×106/mouse purified WT or
DR5-/- T cells on B6 background. Recipient mice were monitored throughout the experimental
period for survival (E), and clinical scores (F) post-transplant. Asterisk indicates statistical
significance: *p<0.05, **p<0.01, ***p<0.001.
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Figure 3.9 DR5 expression on donor T cells in WT or T-bet-/- allogeneic recipients. WT or Tbet-/- B6 mice were lethally irradiated and transplanted with 3×106/mouse purified CFSE-labeled
T cells from FVB donors (n= 3 per group). Four days post-transplant, recipient spleens were
harvested and stained for flow cytometry analysis. Histograms of DR5 expression on donor CD4
or CD8 T cells (A), and on CFSEhigh or CFSElow donor T cells (B) are shown from representative
WT or T-bet-/- recipients in each group.

To test whether Trail/DR5 interaction was responsible for the induction of donor T-cell
apoptosis (Figure 3.2 E and F) and subsequent reduction of GVHD (Figure 3.1) in T-bet-/recipients, we utilized two strategies: blocking Trail/DR5 interaction using sDR5 or using T cells
from DR5-/- donors. While donor T cells exhibited lower levels of expansion and higher levels of
apoptosis in CFSEhigh population in T-bet-/- recipients, the treatment with sDR5 largely
compensated the difference in the absence of T-bet (Figure 3.8 C and D), suggesting that
Trail/DR5 axis contributed to the impaired donor T-cell proliferation and increased early
apoptosis in T-bet-/- recipients. Using DR5-/- mice as donors, we observed that T cells
proliferated slightly faster in the absence of DR5 in vitro (Figure 3.10), but had a comparable
ability to induce GVHD in WT recipients in vivo (Figure 3.8 E and F). While WT T cells
induced severe GVHD in WT recipients, they failed to do in T-bet-/- recipients, reflected by the
overall survival (Figure 3.8E) and GVHD clinical scores (Figure 3.8F). Concersely, DR5-/- donor
T cells were able to induce severe GVHD in the recipients regardless of T-bet expression (Figure
3.8 E and F). These data strongly suggest that the Trail/DR5 interaction is a major signaling
pathway responsible for donor T-cell apoptosis induced by T-bet-/- APCs, through which the
development of GVHD is alleviated.
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Figure 3.10 Ex vivo MLR profile of WT or DR5-/- T cells. Purified WT or DR5-/- splenic T cells
on B6 background were labeled with CFSE, and mixed with CD11chigh splenic DCs from FVB
donor at the ratio of 10:1 (T: DC) in a 96-well plate. Five days later, mixed cells were stimulated
with PMA plus Inomycin and harvested for flow cytometry analysis. Profiles of CFSE and IFN-γ
in donor CD4 or CD8 T cells were shown from representative wells in each group.

3.4.8 T-bet-/- recipients partially maintain GVL effect
We next evaluated whether T-bet-/- hosts may preserve the T-cell mediated GVL effect.
Using A20 B-cell lymphoma with a relatively low dose of T cells, we observed that while donor
T cells induced less severe GVHD in T-bet-/- recipients (Figure 3.11A) as presented above
(Figure 3.1), they mediated a robust GVL effect in either WT or T-bet-/- recipients (Figure 3.11B,
p>0.05). It is notable that the T-bet-/- recipients had delayed lymphoma relapse although
somewhat higher rate in the later stage (Figure 3.11B). Using C1498 atypical myeloid leukemia
with a relatively high dose of T cells, we found that T-bet-/- recipients had significantly better
survival than WT recipients (Figure 3.11C), and most of T-bet-/- recipients were free from
leukemia relapse (Figure 3.11D). In fact, leukemia relapse in those recipients did not occur until
more than 70 days after BMT (Figure 3.11 D and E). Taken together, T-bet expression on the
host is critical for GVHD induction but much less important for mediating the GVL effect. We
91

further observed that donor CD8 T cells expressed comparable levels of CD107a and granzyme
B in T-bet-/- recipients compared with WT recipients (Figure 3.12), which likely contributed to
preserved GVL activity.

Figure 3.11 T-bet-/- recipients partially preserve GVL effect. WT or T-bet-/- BALB/c mice
(n=11~13 per group) were lethally irradiated and transplanted with 5×106/mouse TCD-BM from
WT B6 donors alone, or plus purified T cells from WT B6 donors at 0.25×106/mouse.
Additionally, recipients were i.v. injected with 2×103 A20-luc on BALB/c background at the
time of BMT. Recipients were monitored throughout the experimental period for survival (A),
and tumor growth by luciferin i.p. injection and whole-body BLI. Percentages of tumor relapse
are shown (B). Data pooled from two separate experiments. WT or T-bet-/- B6 mice (n=7~8 per
group) were lethally irradiated and transplanted with 5×106/mouse TCD-BM from FVB B6
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donors alone, or plus 2×106/mouse purified T cells from FVB donors. Additionally, recipients
were i.v. injected with 1×105 C1498-luc generated in B6 mice at the time of BMT. Recipients
were monitored throughout the experimental period for survival (C), and tumor growth.
Percentages of relapse (D) and recipient BLI image (E) are shown. Tumor mortality and GVHD
mortality were distinguished by BLI signal intensity and clinical manifestation of GVHD.
Asterisk indicates statistical significance between WT and T-bet-/- recipients given T cell
transfer: *p<0.05, **p<0.01, ***p<0.001.

Figure 3.12 T-bet on host is not required for CD107a and granzyme B production by donor CD8
T cells. Lethally irradiated WT or T-bet-/- mice on BALB/c background (n=4~10 per group,
pooled from two experiments) were transplanted with 5×106/mouse TCD-BM from Ly5.1+ B6
donor alone, or plus 0.25×106/mouse purified Ly5.2+ T cells from B6 mice. Seven days posttransplant, mononuclear cells were isolated from recipient spleens and stained for flow
cytometry analysis. Percentage of donor CD8 T cell producing granzyme B and expressing
CD107a was shown on gated Ly5.2+ H-2Kb+ CD8+ cells in spleen from representative recipients
in each group.

3.5 Discussion
As the predominant sensors of GVHD initiation, APCs become an attractive target for
GVHD control. After conditioning, residual host hematopoietic APCs, nonhematopoietic APCs,
and donor APCs transferred with the allograft are all capable to prime allogeneic donor T cells
and contribute to GVH reactions (221, 239, 249, 250). Our data demonstrate that T-bet is critical
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for the activity and function of hematopoietic APCs on both host and donor origin to induce
GVHD in MHC-mismatched models (Figure 3.1, 3.6 and 3.7), through regulating donor T-cell
alloresponse (Figure 3.2 A-D), apoptosis (Figure 3.2 E and F), and migration (Figure 3.4). T-bet
on the host also boosts GVHD mediated by CD4 but not by CD8 T cells in miHA-mismatched
BMT model. We further validate that T-bet on hematopoietic APCs, particularly DCs, promotes
allogeneic T-cell response by limiting apoptosis through down-regulating Trail expression
(Figure 3.8).
Either hematopoietic or nonhematopoietic APCs in the recipient are capable of activating
donor T cells and inducing GVHD (219, 221, 249, 250, 261). Our chimeras BMT data
demonstrate that deficiency of T-bet, particularly on host hematopoietic APCs, to a much lesser
extent on nonhematopoietic APCs, attenuated the severity of GVHD (Figure 3.6). DCs are
considered as the most efficacious hematopoietic APCs in T-cell priming and GVHD induction
(68, 243). T-bet has been shown to regulate optimal production of IFN-γ and antigen-specific Tcell activation by DCs (5). Consistently, we also observed impaired IFN-γ production by T-bet-/CD11c+ DCs in the allogeneic but not syngeneic recipients (Figure 3.8A) associated with
compromised allogeneic T-cell activation and proliferation (Figure 3.2), suggesting that T-bet
positively regulates allo-stimulatory functions of DCs.
It is clear that T-cell proliferation, activation and apoptosis in syngeneic recipients were
intact regardless of T-bet expression (Figure 3.3), indicating that T-bet expression on host APCs
does not impact T-cell homeostatic response. In allogeneic BMT, recipient APCs present
alloantigens directly to activate donor T cells, which are essential for GVHD development (68).
The fact that T-bet-/- recipients developed only mild GVHD (Figure 3.1) suggests the essential
role of T-bet in regulating activity of recipient APCs. The first several days post-transplant are
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considered to be critical in GVHD induction according to the studies of spatial and temporal
dynamics of alloreactive T cell activation, proliferation, and tissue distribution (332, 333), and
the most actively dividing T cells are specific for recipient alloantigens in this period of time
(334, 335). Thus, the CFSElow population has been referred as fast-dividing alloreactive T cells,
and CFSEhigh population as slow-dividing non-alloreactive T cells (336, 337). In MHCmismatched BMT (Figure 3.2), the frequency of alloreactive T cells among total donor T cells
should the same in WT or T-bet-/- recipients at the time of transplant. A large proportion of
CFSEhigh T cells undergoing apoptosis in T-bet-/- recipients was likely a dynamic event, in which
alloreactive T cells died before they would be able to further expand. Given T-bet on the host
did not affect T-cell homeostatic response, we surmise that those T cells undergoing apoptosis
trigged by T-bet-/- APCs were alloreactive T cells. Interestingly, the percentages of apoptosis
were comparable among CFSElow T cells in WT or T-bet-/- recipients (Figure 3.2 E and F). It is
possible that those fast dividing CFSElow T cells were undergoing activation-induced cell death
(AICD) through FasL/Fas pathway (338), and the slow-dividing CFSEhigh T cells were instead
sensitive to Trail/DR5-mediated apoptosis as discussed below. Evaluation of the expression of T
cell activation markers, including CD25, CD44, CD69, CD122, and phos-ZAP70, as well as the
cell cycle analysis in CFSEhigh population, would be helpful to further understand the apoptosis
mechanisms.
The apoptosis of donor T cells after allo-BMT appears to be an important process in
regulating T cell homeostasis (339, 340). T-cell apoptosis generally occurrs through two
pathways termed active apoptosis, mediated by death receptor signaling (341, 342), and passive
apoptosis, controlled by bcl-2 family members (343). Active apoptosis has been shown to be one
mechanism to limit the survival of both alloreactive and bystander donor T cells in GVHD (338).
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Death receptors including Fas, TNFR, and DR5, are cell surface receptors that transmit apoptotic
signals initiated by specific TNF family ligands such as FasL, TNF-α and Trail, respectively
(342). Our data shows that T-bet-/- CD11c+ DCs upregulated Trail, but not FasL or TNF-α
expression (Figure 3.8B), to induce allogeneic T cell apoptosis. Signal blockade by sDR5
treatment or using donor T-cell deficient for DR5 (Figure 3.8) further proved our hypothesis that,
the Trail/DR5 axis plays an important role for the alleviated GVHD in T-bet-/- hosts. Our data is
in line with a previous study, which showed that genetically modified Trail-transduced DCs
protected mice from GVHD and leukemia relapse through inducing of apoptosis of both
alloreactive T cells and tumor cells (285).
T-cell migration to GVHD target organs is required for GVHD development. We found
less infiltrated donor CD4 but not CD8 T cells in the livers of T-bet-/- recipiets (Figure 3.4),
which is likely due to the significantly decreased accumulation of CXCR3+ CD4 T cells in the
spleens of those recipients, given the interaction of chemokine and chemokine receptors plays an
important role in mediating T-cell migration to GVHD target organs (312, 313). Previous studies
showed that CD4 and CD8 T cells have distinct characteristics and functions beyond MHC
restriction, where CD8 T cells have survival advantages and lower sensitivity towards apoptosis
than CD4 T cells (344). Indeed, we noticed that, CD8 T cells expressed lower levels of DR5 than
CD4 T cells, particularly in CFSEhigh population, in either WT or T-bet-/- allogeneic recipients
(Figure 3.9B). Not only in apoptosis, but also in activation, proliferation, and migration, CD4 T
cells seemed always to be more sensitive than CD8 T cells on those defects upon interacting with
T-bet-/- APCs in MHC-mismatched BMT (Figure 3.2 and 3.4). These results are further
supported in MHC-matched BMT, where T-bet expression on hosts contributes to the
development of GVHD induced by CD4 but not CD8 T cells (Figure 3.5). A reduced effect of T-
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bet-/- APCs on CD8 T cells may account for the preserved GVL effect (Figure 3.11). More
specifically, we found that CD8 T cells maintained their cytolytic function reflected by preserved
CD107a and granzyme B expression (Figure 3.12).
In conclusion, we demonstrated that T-bet up-regulates IFN-γ production and downregulates Trail expression on recipient DCs, which promotes donor T-cell activation and
mitigates T-cell apoptosis, respectively. T-bet plays a critical role in the development of GVHD
by regulating the activity of hematopoietic APCs, particularly DCs. Taken together with our
recently published findings, we propose that T-bet is a potential therapeutic target for the control
of GVHD through regulating T-cell activation and differentiation as well as APC functions (46).
Although currently unavailable, a small molecular inhibitor to T-bet can be developed, given
other inhibitors to RORγt or c-Rel have been generated as therapeutic intervention in
autoimmunity and transplantation (324, 325). Alternatively, T-bet may be silenced with siRNA
or shRNA strategy as gene-based therapy (345). We are therefore optimistic that our findings
will be translated into the clinic in the near future to benefit patients for controlling GVHD and
leukemia relapse after allo-HSCT.
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Chapter 4: Conclusions and Future Directions

Our study provides insightful mechanisms and proves the concept that targeting T-bet can
largely prevent aGVHD by regulating the functions of both T cells (46) and APCs (48). Previous
investigations of T-bet had mainly focused on its most well-known target IFN-γ. However,
accumulating evidence indicates the existence of T-bet-dependent but IFN-γ-independent
components accounting for the pathogenesis of aGVHD, as well as autoimmune diseases
including EAE (6). The novelty of current study is that, we uncovered for the first time T-bet can
regulate T cell function in an IFN-γ-independent manner. At gene and protein levels, we
identified the molecules that uniquely regulated by T-bet are potentially critical for GVHD
development, and thus may serve as valid targets for the control of GVHD after allo-BMT,
which permits alternative therapeutic strategy rather than directly targeting T-bet given the
transcription factor is generally difficult to be targeted pharmacologically. The novelty of our
current work also lies in the negative regulation of Trail expression on host DCs by T-bet after
allo-BMT, through which T-bet on DCs protects allogeneic T cells from apoptosis. Altogether,
we found that T-bet positively regulates activation and function of both T cells and DCs, which
sets a strong rationale to pharmacologically inhibit T-bet for the control of GVHD through both
T cells and APCs synchronously.
Further studies are required to address remaining unsolved questions and translate our
findings towards clinic application. The gene-based therapy (345) using siRNA or shRNA to
silence T-bet could be a direct targeting strategy due to the lack of small molecular inhibitor
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specific for T-bet. Mice transferred with siRNA-T-bet transfected splenocytes failed to develop
EAE (49), and administration of siRNA-T-bet has been suggested could effectively alleviate
established EAE in mice (346). Our pilot experiments indicate that a single dose of siRNA-T-bet
(50µg/mouse) on the day of BMT failed to significantly ameliorate the overall GVHD severity
(unpublished observation). Thus, the optimal dose and treatment period of siRNA-T-bet as a
prophylaxis under allo-BMT settings will require further investigation.
Transcription factors generally working in pairs by forming the complex and generating
chromatin modifications that associated with gene activation or repression. Same is true for T-bet
to perform its translational regulation on T cell differentiation (2, 347). T-bet recruits JMJD3 (a
histone H3K27 demethylase) and SET7/9 (a histone H3K4 methyltransferase) to transactivate
Ifng gene and promote Th1 differentiation. This process is further enhanced by HLX and
RUNX3, the transcription factors encoded by T-bet target genes Hlx and Runx3. T-bet binds to
RUNX3 to silence Il4 gene and it also prevents the GATA3-mediated activation of Th2-related
cytokine genes Il4, Il5 and Il13by binding to GATA3. Similarly, T-bet interacts with RUNX1 to
suppress Th17 differentiation, and recruits BCL6 to block Tfh lineage commitment. These
enzymes or transcription factors form complex with T-bet could also be the potential target for
the prevention of aGVHD. For example, JMJD3 has recently been suggested a critical role in
regulating CD4 T-cell differentiation in a Th1-dependent colitis model. Deficiency of JMJD3
inhibits Th1 differentiation while promoting Th2 and Th17 generation (348). The small molecule
inhibitor GSK-J1 that is selective for the JMJ subfamily (JMJD3 and UTX) is currently available
(349, 350). Inhibitors for SET7/9 were identified by the high-throughput screening (351),
although the effect of SET7/9 in the development of GVHD has not been tested.
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Alternatively, indirectly targeting downstream effectors of T-bet on T cells, such as those
T-bet-dependent but IFN-γ-independent molecules (e.g. CXCR3, NKG2D) we identified, is
presumably providing a beneficial outcome, as suggested by others (314, 323) and our
unpublished work. Our preliminary data indicate that, blocking NKG2D using its mAb could
effectively attenuate aGVHD in mice. One limitation is the lack of proven of those genes we
identified are unique target genes directly controlled by T-bet, which could be defined and
confirmed by using the chromatin immunoprecipitation (ChIP) assays. On the aspect of APCs,
genetically modified DCs (e.g. over-expressing Trail) may be effective to combat aGVHD by
inducing alloreactive T cell apoptosis while preventing leukemia relapse (285). This is in line
with our observation in allo-BMT settings, where T-bet upregulates Trail in DCs and prevents
the early apoptosis of allogeneic donor T cells, although we have not determined whether the
deficiency of T-bet in DCs also induce the apoptosis of tumor cells.
Another option is to modify upstream regulators of T-bet. MicroRNAs (miRs) have the
potential for novel therapeutics in GVHD (352, 353), as suggested by different studies done by
us and others. MiR-17-92 (354), miR-155(355), miR-34a (356), miR-100 (357), and miR-142
(358) have all been implicated a significant role in GVHD. Further investigation on miR-29 to
regulate GVHD is attractive due to inhibition of IFN-γ production by repressing both T-bet and
Eomes (22). Moreover, recent studies suggest that, T-bet could be regulated by the histone
metyltransferase Ezh2, at both transcriptional and posttranslational levels (359). Ezh2 can
directly activate Tbx21 transcription by binding to its promoter in Th1 cells, while Ezh2 is also
required to protect T-bet degradation mediated by proteasome. Follow-up study showed that
conditional loss of Ezh2 in donor T cells could attenuate GVHD while still preserve the GVL
effect after allo-BMT (360). The tyrosine kinase c-Abl has been reported to catalyze the tyrosine
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phosphorylation of T-bet DNA-binding domain and therefore enhance the transcriptional
activation of T-bet and Th1 differentiation (361). Combinational inhibition of c-Abl and PDGF
receptors using imatinib or nilotinib could protect against murine sclerodermatous cGVHD
(362). The intervention of c-Abl in the prevention or treatment of aGVHD has not yet been
evaluated.
Taken together, by using the genetically knockout mice, we have proved that targeting Tbet can prevent aGVHD and leukemia relapse, with additional IL-17 neutralizing Ab treatment
when necessary. The next step is to achieve the translational application. As discussed above, it
is challenging but promising to develop the therapeutic strategies to target T-bet or its related
pathways to control GVHD and prevent leukemia relapse after allo-HSCT.
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